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Abstract

RISK FACTORS FOR POSTOPERATIVE COGNITIVE DYSFUNCTION IN OLDER
ADULTS UNDERGOING MAJOR NONCARDIAC SURGERY
By: Osama Ali Shoair, PhD
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2013
Major Director: Patricia W. Slattum, Pharm.D., Ph.D.
Associate Professor and Director of Geriatric Pharmacotherapy Program
Department of Pharmacotherapy and Outcomes Science

Background: Postoperative cognitive dysfunction (POCD) is a deterioration in cognitive
function that occurs after surgery as measured by neuropsychological tests. The purpose of this
study was to determine the incidence and risk factors for POCD in older adults three months
after major noncardiac surgery.
Methods: This is a prospective study of patients aged 65 years and older who underwent major
noncardiac surgery. Patients’ cognitive function was assessed before and three months after
surgery using a computerized neurocognitive battery. Blood samples were withdrawn from
patients before surgery to identify patients with high level of C-reactive protein (CRP), and
patients who had the apolipoprotein-E4 (ApoE4) allele, as potential inflammatory and genetic
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biomarkers for POCD, respectively. A nonsurgical control group, that is similar to patients in
age, education level, and computer familiarity, was recruited to adjust for learning effects from
repeated administration of neurocognitive tests. Patients were classified as having POCD if they
had less than -1.96 in the individual Z-scores of two or more tests or in the composite Z-score.
Results: A total of 69 patients and 54 controls completed the study. The mean age for patients
was 71 ± 5.4 (65–88) years old and 66.7% of them were females. The majority of patients
(78.3%) had above high school education. There was no difference between the surgical and
nonsurgical groups in demographics except for age which was marginally higher in the
nonsurgical group [73 ± 6.3 (65-92)].
The incidence of POCD was 15.9% three months after surgery. Multivariable logistic regression
showed that carrying the ApoE4 allele (OR = 4.74, 95% CI = 1.09 – 22.19), using one or more
highly anticholinergic or sedative-hypnotic drugs at home prior to surgery (OR = 5.64, 95% CI =
1.35 – 30.22), and receiving sevoflurane for anesthesia (OR = 6.43, 95% CI = 1.49 – 34.66) were
risk factors for POCD.
Conclusion: The incidence of POCD in older adults is 15.9% three months after major
noncardiac surgery. Risk factors for POCD were carrying the ApoE4 allele, using one or more
highly anticholinergic or sedative-hypnotic drugs at home prior to surgery, and receiving
sevoflurane for anesthesia.

CHAPTER 1: INTRODUCTION

Postoperative cognitive dysfunction (POCD) is a deterioration in cognitive function that
occurs to patients after surgery as compared to their preoperative cognitive status. POCD is not a
new phenomenon and it has been well-documented in the literature for a very long time. About
fifty five years ago, Bedford published a retrospective observational report of 251 older patients
over the age of 65 years who experienced deterioration in their cognitive function after surgery
as was described by the patients or their family members.1,2 He observed, without performing
any neuropsychological testing, that a minor degree of dementia was present in this group and
that 7% of them experienced severe dementia to the extent that he suggested that “operations on
elderly people should be confined to unequivocally necessary cases”.1 Most of the research
initially focused on POCD in cardiac surgery since the proportion of patients who experienced
decline in cognitive function after this type of surgery was large compared to other types of
surgery. POCD is now recognized as a potential complication of cardiac surgery and current
research is trying to elucidate the risk factors of POCD in this type of surgery, particularly the
role of cardiopulmonary bypass (CPB) in contributing to POCD.3 In contrast, the research about
the incidence and risk factors of POCD after noncardiac surgery is still in its infancy, and the
results of current research in this area is still conflicting and inconclusive.

I. DEFINITION OF POCD
Currently, there is no consensus definition of POCD in the literature. For research
purposes, POCD is generally defined as a decline or deterioration in cognitive function that
occurs in patients after surgery when compared to their preoperative cognitive status as measured
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by neuropsychological testing. This decline is usually subtle in nature and is observed most of
the time by the patients, their caregivers, or close friends. A statement from a patient such as “I
am not the same” after surgery can simply represent the patient’s lay language of having POCD
in the absence of a gold standard tool to diagnose it. POCD can affect different cognitive
domains including verbal memory, visual memory, processing speed, cognitive flexibility, and
executive function.4 Due to its often subtle nature, the condition can usually be missed by
clinicians, and an appropriate battery of neurocognitive tests, that is sensitive to subtle changes in
cognitive function and covers a wide array of cognitive abilities, is necessary to determine if a
patient is having POCD.
The risk of POCD may be increased in older adults due to various changes associated
with physiology of aging. Cerebral changes occur to the brain as we age including reduction of
the complexity of neuronal connections, reduction of the synthesis of neurotransmitters, and
increase in the postsynaptic degradation of neurotransmitters.5 The changes may also include
decreased regional brain volume, impaired serotonin, acetylcholine, and dopamine receptor
binding and signaling, accumulation of neurofibrillary tangles, and altered concentrations of
various brain metabolites.6-11 There are also pharmacokinetic and pharmacodynamic changes that
progressively occur with aging.12 Pharmacokinetic changes include a reduction in renal and
hepatic clearance and increase in volume of distribution of lipid soluble drugs resulting in
prolongation of elimination half-life of several drugs.12 Pharmacodynamic changes involve
altered, usually increased, sensitivity to several classes of drugs including medications with
anticholinergic and sedative properties that are known to cause negative cognitive outcomes.12
These changes may also cause the brain of older patients to have less tolerability to anesthetic
drugs and other highly anticholinergic and sedative-hypnotic medications during the surgery
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which may increase vulnerability of older adult patients to neurologic deterioration and various
insults that happen to the brain during surgery.

II. INCIDENCE OF POCD
The reported incidence of POCD in the literature after both cardiac and noncardiac
surgery is enormously variable and should be interpreted cautiously. This is due to several
factors including the wide variability in the definition of POCD, number of cognitive domains
assessed, number and type of neurocognitive tests used to assess each cognitive domain, time of
pre- and postoperative assessment of cognitive function, type of surgery and anesthesia, and the
use of a control group to adjust for learning effects from repeated administration of
neurocognitive tests. The incidence of POCD has been reported to be 30 – 80% a few weeks
after cardiac surgery, and 10 – 60% after three to six months.2 The first International Study of
Postoperative Cognitive Dysfunction (ISPOCD1) reported the incidence of POCD after major
noncardiac surgery to be 25.8% one week after surgery and 9.9% after 3 months.13 Newman et
al. conducted a meta-analysis showing that the incidence of POCD after noncardiac surgery in
studies published until December 2005, ranged between 6.2% and 56% 22 days and up to six
months aftersurgery.1 Ignoring the one study with very high incidence of POCD, the incidence
range was between 6.2% and 9.4%.1 These reports reveal how difficult it is to obtain accurate
estimates of the incidence of POCD after different types of surgery. As mentioned earlier, this is
due to the wide variability in the methodology used to determine the incidence of POCD. This
also makes it very difficult to compare the results of different POCD studies.
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III. POSTOPERATIVE DELIRIUM (POD) AND POCD
POCD may be confused with postoperative delirium (POD), and may mistakenly be
considered as part of the same continuum. However, despite their similarities, POCD and POD
are two distinct phenomena. POD is well defined in the World Health Organization’s
classification of diseases (ICD-10) and the Diagnostic and Statistical Manual for Mental
Disorders [fourth edition, text revision] (DSM-IV-TR).14 POD is characterized by an acute onset
of altered consciousness, disorientation, and confusion which starts hours to days after surgery
and can last for days to weeks. In most patients, POD often occurs within the first three days
after surgery.14 Attention is usually impaired in POD and may be associated with fluctuation in
consciousness.14 POD is usually reversible especially if the clinician can determine its
underlying cause.14 POD can be assessed using several valid and reliable tools such as the
Confusion Assessment Method (CAM).15
On the other hand, POCD does not have a consensus definition or ICD diagnostic codes
and its onset is subtle in nature. POCD is generally not well-characterized and the major
complaint of patients with POCD would be a general deterioration in memory or other cognitive
domains that may make it hard enough for some patients to manage their job or daily activities.14
The onset of POCD usually occurs within weeks to months after surgery and may last for years
or become permanent. The number and type of affected cognitive domains in POCD widely
vary, but consciousness is not altered in POCD.14 POCD may be reversible but it can also be
long lasting in some patients.14 There is no current consensus on the number or type of
neurocognitive tests that should be used to diagnose POCD. Table 1 summarizes the major
differences between POCD and POD.
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IV. LONG-TERM CONSEQUENCES OF POCD
POCD is a serious phenomenon and should not be underestimated by patients, caregivers,
or clinicians. Monk et al. showed an association between POCD and increased mortality in
patients in the first year after major noncardiac surgery.17 Patients with POCD at hospital
discharge were more likely to die before the three-month follow-up cognitive testing, and
patients who continued to have persistent POCD after three months were at higher risk of death
in the first year after surgery.18 Another study showed that POCD after noncardiac surgery was
associated with increased mortality, decreased quality of life, risk of early withdrawal from the
workforce, and increased dependency on society.19,20

Table 1. Summary of Major Differences between POCD and POD (Adapted from Krenk et al.)14
Features

POD

POCD

Definition and Severity

ICD-9/10, DSM-IV-TR

Controversial

Incidence

4 – 54%16

7 – 71%1

Onset

Acute (hours to days)

Subtle (weeks to months)

Duration

Days to weeks

Weeks to years

Cognitive Changes

Attention

Multiple/Variable

Consciousness

Altered

Normal

Reversibility

Usually reversible

May be reversible

V. RISK FACTORS FOR POCD
The mechanisms and risk factors for POCD are still unknown, and POCD is likely a
multifactorial condition. The next chapter will discuss three major theories in the current
literature that may play a role in the development of POCD. The first theory is related to surgery
5

and it includes several factors such as type of surgery, possible neuroinflammation during
surgery, postoperative delirium, and postoperative complications. The second theory is
concerned about medications being administered to the patients including home medications
prior to surgery, anesthesia and sedation during surgery, and postoperative analgesics. The third
theory puts the ‘fault’ on the patient and suggests that POCD may be associated with patient’s
age, education level, predisposition with certain genes related to cognitive deterioration, and
other factors. The next chapter will elaborate in detail on each of these variables and the
literature supporting it.

VI. SUMMARY
POCD does not have a consensus definition in the literature, but it can be generally
defined as a deterioration in patients’ cognitive function after surgery compared to their
preoperative cognitive status as measured by neuropsychological testing. POCD has primarily
been documented after cardiac surgery, but it has been recently reported after noncardiac surgery
as well. POCD is usually subtle in nature and may be underestimated by clinicians. The
incidence of POCD in the literature widely varies depending on the definition of POCD, number
of cognitive domains assessed, number and type of neurocognitive tests used to assess each
cognitive domains, time of pre- and postoperative assessment of cognitive function, type of
surgery and anesthesia, and the use of a control group to adjust for learning effects. POCD is
usually confused with POD after surgery though they are different in the onset, duration,
cognitive changes, alteration of consciousness, and possible reversibility. POCD has long-term
consequences that may range from decreased quality of life to mortality. The risk factors for
POCD are still unknown and POCD is likely to be multifactorial. Potential risk factors for POCD
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may be related to surgery, medications, or the patient. The next chapter will discuss these risk
factors in detail and the literature supporting them.
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CHAPTER 2: LITERATURE REVIEW

I. ETIOLOGY AND RISK FACTORS OF POCD
The etiology and pathophysiologic mechanisms of POCD remain unknown and POCD is
likely a multifactorial condition. Currently, there are three major theories that may explain
POCD: medication, surgery, and patient theories.1,2 Each of these theories includes several
potential risk factors for POCD. First, there is the medication theory which suggests that certain
anesthetic and sedatives agents administered during and after the surgery may be etiological in
POCD, particularly those medications with highly anticholinergic or sedative properties. This
theory also extends to medications that the patient has been chronically using at home prior to his
admission to surgery. Second is the surgery theory that is inclusive of factors related to the type
and duration of the surgery, intraoperative conditions and physiologic changes that occur during
the surgery, possible inflammation or traumatic injury to the brain, postoperative delirium, length
of hospitalization, and postoperative complications such as infection or respiratory depression. A
third theory suggests that it might not be the medication or the surgery theories, and that it is
basically the patient’s ‘fault’.1 This theory suggests that patients’ age, cognitive reserve or the
ability to sustain neurologic insults, pre-existing cognitive impairment before surgery, genetic
predisposition related to dementia such as the apolipoprotein-E4 (ApoE4) allele, chronic
depression or anxiety prior to surgery, alcoholism or chronic smoking, and their comorbidities
may be associated with the risk of POCD. Figure 1 shows a summary of the three current major
theories and risk factors of POCD. The most important candidate risk factors that might play
independent or collaborative roles in the genesis of POCD will be discussed in detail.
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Figure 1. Major Theories and Risk Factors of POCD

MEDICATIONS
• Anesthesia/Sedation
• Home medications
• Perioperative medications
• Postoperative medications

PATIENT

SURGERY

• Age
• Cognitive reserve
• Cognitive impairment
• Genetic biomarkers
• Comorbidities

• Type and duration
• Intraoperative conditions
• Neuroinflammation
• Brain Injury Biomarkers
• Postoperative delirium
• Complications

A. MEDICATIONS
1. Anesthesia/Sedation
The role of general anesthesia (GA) in causing cognitive dysfunction has often been
described as a potential risk factor for POCD especially in older adults.3 Animal studies showed
that long exposure to common anesthetic agents can cause cell damage and apoptosis.4 JevtovicTodorovic et al. found cell death in rat brains after exposure to midazolam, nitrous oxide, and
isoflurane, and when combining all three agents, there was a significant decline in their memory
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and learning skills.4 However, these observations might not be transferable to humans and there
is a need to accumulate evidence in humans to determine if they are related to the type, duration,
or depth of anesthesia. Few studies have been conducted to evaluate if there is an association
between POCD and the type of anesthesia [general (inhaled, intravenous), regional (spinal,
epidural, or nerve block), or both general and regional anesthesia], duration of anesthesia, and
depth of anesthesia. Also, there is an increased interest in studying the risk of POCD associated
with the use of sedative agents during surgery.
Rasmussen et al. randomized 428 patients aged 60 years and older undergoing major
noncardiac surgery for GA versus regional anesthesia (RA).5 They evaluated patients’ cognitive
function seven days and three months after surgery finding a significant difference in POCD
incidence at seven days between the GA and RA groups [21.2% versus 12.7% (p = 0.04)],
respectively.5 However, at the three-month follow-up, there was no significant difference in the
incidence of POCD between the two groups (14.3% after GA and 13.9% after RA).5 Evered et al.
also compared the incidence of POCD three months postoperatively after GA and RA, but they
could not find a significant difference (21% vs. 16%, respectively).6 They concluded that POCD
is independent of the type of anesthesia used during the surgery.6 Mason et al. conducted a metaanalysis to compare the influence of general, regional, or a combination of GA and RA on the
development of POCD.7 They compared the incidence of POCD when patients were
administered GA versus individual types of RA and also the combination of GA and RA, but
they could not find a significantly higher incidence of POCD with any of these comparisons.7
This meta-analysis was limited by the major weakness of all POCD studies which is the
difficulty of combining and comparing different studies due to the wide variability in
methodological techniques of POCD assessment.

13

There is a scarcity of research to evaluate the relationship between the duration of
anesthesia and POCD. Moller et al. evaluated the duration of anesthesia as a risk factor for
POCD in a group of 1218 older patients 60 years and above undergoing major noncardiac
surgery at seven days and three months.8 They compared the difference in POCD incidence
when patients were under anesthesia for a duration of 120 minutes or less, 121 – 240 minutes,
and 241 minutes or longer.8 They found that the duration of anesthesia was associated with
POCD incidence at seven days (18%, 24%, and 33%, respectively) but not three months after
surgery (11%, 9%, and 11%, respectively).8
A few studies have evaluated the depth of anesthesia as a risk factor for POCD.
Steinmetz et al. studied 70 patients aged 60 years or older who underwent major noncardiac
surgery.3 The depth of anesthesia was monitored using the cerebral state monitor, which
provided a cerebral state index (CSI) value.3 The duration of anesthesia was not different in
patients with deep anesthesia (CSI < 40) and light anesthesia (CSI > 60).3 They were not able to
find a significant difference in the incidence of POCD between the two groups at seven days
after surgery and they did not do any further follow-up.3 However, this study was underpowered
and there was the possibility of type II error.3 Farag et al. randomized 74 patients older than 50
years to either a lower Bispectral Index (BIS) anesthesia regimen (median = 39) or a higher BIS
regimen (median = 51) during the surgical procedure.9 Patients’ cognitive status was assessed
preoperatively and four to six weeks after surgery using a cognitive battery that included tests to
measure processing speed, working memory, and verbal memory.9 Processing speed was the
only significantly different test between the two groups with higher processing speed observed in
the group with lower BIS or deeper depth of anesthesia. There was no significant difference
between the two groups with the other two cognitive tests.9 Chan et al. randomized patients 60
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years or older undergoing any elective major surgery to receive BIS-guided anesthesia or routine
care.10 There was a significant difference between the two groups in depth of anesthesia (BIS
median = 53 and 36; p < 0.001, respectively).10 There was no significant difference between the
two groups in cognitive function seven days after surgery.10 However, three months after the
surgery, the patients in the BIS-guided group with lighter depth of anesthesia had a lower
incidence of POCD compared with the routine care group with deeper level of anesthesia (10.2%
vs. 14.7%; adjusted odds ratio (OR) = 0.67; 95% confidence interval (CI) = 0.32 – 0.98; p =
0.025).10 This study suggests that lighter depth of anesthesia is associated with better long-term
cognitive outcomes after major surgery.
Royse et al. investigated the influence of propofol or desflurane on the incidence of
POCD in a randomized trial of 180 patients undergoing coronary artery bypass surgery
(CABG).11 They found that the incidence of POCD was significantly higher with propofol
compared with desflurane when they assessed patients’ cognitive function three to seven days
after surgery (67.5% vs. 49.4%, respectively; p = 0.018).11 However, there was no difference in
the incidence of POCD with propofol compared with desflurane at three months after surgery
(11.2% vs. 10.0%, respectively).11 The results of this study show that propofol may increase the
risk of short-term POCD after cardiac surgery. Höcker et al. randomized patients 65 years and
older undergoing elective abdominal or urologic surgery to receive anesthesia with sufentanil
and either propofol or xenon.12 Patients’ cognitive function was assessed one, six, and thirty days
after surgery.12 The study also showed a high incidence of POCD with the use of propofol during
the month following surgery, but the incidence was not significantly different when propofol was
compared to xenon (50% vs. 44% at 1 day, 18% vs. 12% at 6 days, and 12% vs. 6% at 30 days,
respectively).12 Kadoi et al. also examined the effect of propofol and fentanyl on increasing the
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risk of POCD in a group of 180 older patients after CABG who were randomized to receive
either propofol or fentanyl.13 All patients received 10 mg of diazepam by mouth one hour before
anesthesia which was induced by 0.3 mg/kg midazolam, 10 g/kg fentanyl, and 0.2 mg/kg
vecuronium.13 There was no significant difference in POCD at 6 months between the two groups
(propofol: 6% vs. fentanyl 7%).13 The results of these studies make it evident that there is still
conflicting information regarding the association between certain anesthetic/sedative agents and
the risk of POCD.

2. Home and Perioperative Medications
Home medications are any drugs the patient has been taking prior to admission for
surgery. Perioperative medications are any drugs given to the patient once he has been admitted
for surgery and until discharge from the post-anesthesia care unit (PACU) after the surgery. The
main concern is related to medications with anticholinergic or sedative properties that are
particularly known to be associated with negative cognitive outcomes in older patients.14 The
age- and disease-associated changes in brain neurochemistry and the way the brain handles such
medications in older patients make them more likely to develop cognitive impairment than
younger patients.14 The hypothesis is that the cumulative harmful effects of home medications
along with those medications being administered during surgery in addition to the anesthetic and
surgical experience can combine together to insult the brain enough to cause POCD. There is not
much research that has been done about the use of anticholinergic or sedative medications and
increased risk of POCD. Most of the research done has been about the relationship between these
medications and development of POD. However, POD has been associated with POCD and risk
factors for POD might play a role in the development of POCD.15,16 Recent studies have
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suggested that the total burden of anticholinergic drugs may determine the development of
delirium rather than any single agent.14 There are several drugs with anticholinergic
characteristics that are prescribed with high frequency to patients during and after surgery.
Examples of these drugs are antihistamines (H1-blockers), antidepressants, antipsychotics,
antiepileptics, anti-emetics, and muscle relaxants.17 Tune et al. investigated found a significant
association between serum levels of anticholinergic drugs and POD in patients undergoing
cardiac surgery.18 Patients with POD had significantly higher serum level of anticholinergic
drugs (p < 0.001).18
Benzodiazepines (BDZs) is another group of medications that is frequently prescribed in
older patients. They are used to manage anxiety and insomnia in the elderly, and even often
prescribed to manage depressed older adults.19 Many older patients are treated with BDZs for
prolonged periods, and long-term use of BDZs can accelerate cognitive decline in these
patients.19 Despite these concerns, epidemiologic data indicate that benzodiazepines are among
the drugs most commonly prescribed to older adults.20 Among community-dwelling older adults,
10 – 30% report using a benzodiazepine at any given time, with approximately half of those
being long-term users.20 There are very few studies that investigated the relationship between
BDZs and POCD. A study of older patients undergoing cataract surgery found a statistically
significant relationship between the amount of nitrazepam administered and memory decline
during the first postoperative week.19
Another study by Rasmussen et al. hypothesized that diazepam and its active metabolites
could be detected in blood after abdominal surgery in 35 patient 60 years and older.19 They
found a POCD incidence of 48.6%, however; the concentration of diazepam or its metabolite
desmethyldiazepam was not associated with POCD.19 Another study investigated the relationship
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between POD and duration of BDZs exposure in 328 patients aged 65 to 80 years old who
underwent orthopedic surgery.21 POD occurred in 26% of BDZs users versus 13% in nonusers (p
< 0.01) and the incidence was significantly different in long-term BDZs users (daily use for > 1
year) than short-term users (daily use for < 1 year) [35% vs. 10%, respectively].21

3. Postoperative Medications
Postoperative medications are drugs taken by the patient after discharge from the PACU
and until hospital discharge. Most of the medications administered to the patients at this stage are
analgesics, especially opioids being the most commonly used medications for postoperative pain.
They are usually administered either orally, intravenously by a nurse, or through intravenous
patient-controlled analgesia (PCA). There are reports that the potency of opioids is increased in
older adults due to their increased peripheral compartment concentration and longer duration of
action.22 Older patients also increased sensitivity to the effects of BDZs and slower metabolism
of long-acting agents.23,24 On the other hand, there is a debate that leaving the patient with
inadequate pain control can put the patient at risk of the same outcomes in addition to
unnecessary distress, depression, and sleep disturbance.22 Deterioration in sleep can cause
hyperalgesia which worsens sleep further and increases the need for opioids causing a vicious
cycle that can have an indirect negative cognitive outcome.22 Few studies have been conducted
to investigate the relationship between different analgesics, their doses, and route of
administration and the risk of POCD and POD.
Marcantonio et al. studied the association between psychoactive medications used
postoperatively and POD in a case-control study involving 91 patients.25 They found that POD
was significantly associated with postoperative exposure to meperidine (OR = 2.7; 95% CI = 1.3
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– 5.5) and to BDZs (OR = 3.0; 95% CI = 1.3 – 6.8).25 There was no significant difference in the
association between meperidine use and POD whether administered via epidural or PCA.25 They
also found that long-acting (OR = 5.4; 95% CI = 1.0 - 29.2 vs. 2.6; 1.1 - 6.5) and higher doses of
BDZ (OR = 3.3; 95% CI = 1.0 - 11.0 vs. 2.6; 0.8 - 9.1) were significantly associated with higher
risk of POD25. They could not find a statistically significant association between POD and either
narcotics or anticholinergic drugs.25 Wang et al. conducted a prospective cohort study of 225
patients 65 years and older undergoing noncardiac surgery and they assessed patients’ cognitive
function on days one and two after surgery and they found that 13% of patients experienced
POCD on day one, 7% on day two, and 15% had POCD on either day one or day two after the
surgery.26 They also found that the only predictive factor for POCD was postoperative analgesia
with opioids, and that patients who received postoperative analgesia orally were at significantly
lower risk for the development of POCD (OR = 0.22; 95% CI = 0.06 – 0.80).26 However, this
study assessed POCD too soon after surgery when the patients were still recovering from
anesthesia and were under the effect of several medications including sedatives and analgesics.
There is always the possibility of confusing POCD with POD when assessing POCD too soon
after surgery like in this study. It is also more important to determine if POCD persists on the
long-term to confirm that it is not just a temporary condition that occurs during hospitalization of
the patients then becomes reversible. Vaurio et al. demonstrated a similar association between
postoperative use of opioids via PCA and increased risk of POD compared with patients who
used opioids orally.22 These studies show that pain and pain control are important factors to
consider after surgery especially in older patients who may be at higher risk, and that more
studies are needed to accumulate enough evidence to guide the pain management practices in this
population in a way that prevents or minimizes POD and POCD.
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B. SURGERY
1. Type of Surgery
POCD research initially focused on cardiac surgery due to its invasiveness and the
severity of complications. There was also an assumption that POCD risk may be higher in onpump versus off-pump CABG. There was lack of interest in studying POCD after noncardiac
surgery until Moller et al. conducted the large ISPOCD1 study in a group of 1218 older patients
and showed that POCD was found in 25.8% of study patients one week after surgery and in 9.9%
at three months.8 Evered et al. conducted a recent study to determine the association between
surgery type and incidence of POCD after procedures involving light sedation, general
anesthesia for noncardiac surgery, and general anesthesia for cardiac surgery involving
cardiopulmonary bypass.6 The study included three surgical groups (n = 644) [coronary
angiography (CA) under sedation, major noncardiac surgery (total hip joint replacement [THJR]
surgery) under general anesthesia, and CABG surgery under general anesthesia) and one nonsurgical control group (n = 34).6 The incidence of POCD one week postoperatively was 17% for
THJR surgery and 43% for CABG surgery (adjusted OR = 0.2, 95% CI = 0.1 - 0.4; p < 0.01).6 At
three months, the incidence of POCD was 21% for CA under sedation, 16% for THJR surgery,
and 16% for CABG surgery.6 The mean difference in proportions of POCD among groups was
0.00 (-0.07, 0.07) for CABG versus THJR; -0.05 (-0.12, 0.03) for CABG versus CA; and -0.05 (0.13, 0.03) for THJR versus CA and there were no significant differences among the three
groups (adjusted OR = 1.21, 95% CI = 0.94, 1.55; p = 0.13). They concluded that the incidence
of POCD is independent of the type of surgery.6 There was no significant difference at three
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months after surgery even between major noncardiac surgery and CABG surgery which is
hypothesized to be a major risk factor for POCD in cardiac surgery.

2. Intraoperative conditions
There is a hypothesis that certain irregularities in intraoperative conditions may
contribute to increasing the risk of POCD. The major four intraoperative variables that have been
considered in the literature as potential risk factors for POCD are hyperthermia, hypotension,
hypoxemia, and cerebral embolism. The degree and duration of these conditions also may play a
role in the severity of POCD.
Moller et al. conducted a study in 736 patients undergoing major noncardiac surgery with
general or regional anesthesia to determine if intraoperative monitoring with pulse oximetry to
reduce the risk of hypoxemia would decrease the incidence of POCD.27 They randomized
patients to undergo pulse oximetry monitoring (group 1) or not (group 2).27 There was no
significant difference between the two groups in the incidence of POCD when it was assessed
one week and three months after surgery.27 In the ISPOCD1 study, Moller et al. assessed the
incidence of POCD in patients who experienced hypoxemia (defined as one or more episodes of
oxygen saturation ≤ 80% for > 2 minutes) or hypotension (defined as one or more episodes of
mean arterial pressure ≤ 60% for ≥ 30 minutes) one week and three months after surgery.8 The
incidence of POCD was 26% and 11% in patients with hypoxemia and 26% and 9% in patients
with hypotension, respectively.8 However, they could not find a significant association between
different degrees and durations of hypoxemia or hypotension and the incidence of POCD after
one week or three months.8 In some surgical procedures that require dry fields or that are
associated with substantial blood loss, anesthesia under deliberate hypotensive conditions can be
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beneficial to the patient, but it can also result in ischemic injury in nonsurgical regions, such as
the brain and heart.28 William-Russo et al. randomized 235 older adults undergoing total hip
replacement with epidural anesthesia to one of two levels of intraoperative mean arterial blood
pressure management (45 – 55 mmHg or 55–70 mmHg).28 There was no significant difference
between the two groups in the incidence of POCD one week or four months after surgery.28 The
current few studies in the literature indicate that there is no significant association between
hypotensive or hypoxemic conditions and the risk of POCD.
Thromboembolic events may potentially cause cognitive deficits due to ischemic tissue
damage.4 Rodriguez et al. conducted a study in a convenience sample of 37 patients undergoing
total knee arthroplasty (TKA) to investigate the relationship between cerebral emboli and the risk
of POCD at one week and three months after surgery.29 Cerebral emboli occurred in 59.5% of
study patients and the incidence of POCD was 41% at one week compared to 18% after three
months.29 However, they could not find a significant association between intraoperative cerebral
emboli and POCD.29 Liu et al. tried to test the hypothesis that off-pump CABG surgery is
associated with decreased number of cerebral microemboli and the incidence of POCD.30 They
included 227 Chinese patients undergoing CABG surgery (59 on-pump vs. 168 off-pump) and
assessed cognitive function one week and three months after surgery.30 Though, the group with
off-pump CABG surgery had a significantly decreased number of cerebral microemboli, there
was no significant difference in the incidence of POCD between the two groups either at one
week (55.2% vs. 47.0%; p = 0.283, respectively) or three months (6.4% vs. 13.1%; p = 0.214)
after surgery.30 They also found that neither on-pump surgery nor cerebral microemboli was
associated with POCD.30 The authors acknowledged some of the limitations of this study such as
the lack of randomization and potential bias in patient allocation.30 Also, there was a difference
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in the baseline of one of the cognitive tests in favor of the off-pump group.30 The results of these
studies show that there is a need for more research in this area to address these limitations and
accumulate enough evidence to answer the question if cerebral embolism may be a risk factor for
POCD.
Only a few non-conclusive studies have been published about the relationship between
changes in body temperature during surgery especially hyperthermia and the risk of POCD.
Plourde et al. randomized 62 patients 40 – 70 years old undergoing cardiac surgery to either cold
or warm CPB (28 °C vs. 36 °C, respectively) and they measured their cognitive function seven
days postoperatively.31 Only 54 patients completed the study (cold CPB = 24; warm CPB =
30).31 There was a significant postoperative deterioration in both surgical groups, but no
differences were observed between groups.31 However, this study was limited by the small
sample size, absence of a control group to adjust for learning effects from repeated
administration of the neuropsychological tests, and the assessment of POCD at seven days only
and not on the long-term.31 Grigore et al. also hypothesized that hypothermic CPB would
decrease the cognitive deterioration after CABG surgery.32 They recruited 227 patients
undergoing elective CABG surgery who were randomized to either normothermic (35.5 –
36.5°C) or hypothermic (28 – 30°C) CPB and they measured cognitive function six weeks after
surgery.32 There was no difference in cognitive outcomes between normothermic and
hypothermic groups.32 Salzar et al. randomized 150 patients over 65 years of age who were
scheduled for total knee replacement to receive standard temperature control (covered with a
sheet with no active warming) or active warming (infusion of warmed fluids).33 They could not
find any difference between the two groups in the incidence of POCD three months after the
surgery (standard care = 14.3%, active warming = 6.5%; p = 0.2440).33 These studies show that
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there is no evidence yet that body temperature during surgery plays a role in determining the
incidence of POCD.

3. Neuroinflammation and Brain Injury Biomarkers
There is a hypothesis that perioperative inflammatory response may be a risk factor for
POCD in older adults.34 Neuroinflammatory response can result from brain trauma during
surgery.34 Inflammation during surgery can induce a number of pro-inflammatory cytokines
leading to a systemic acute-phase response, ‘the illness response’.4 The key cytokines that may
play a role in the inflammatory process during surgery are interleukin-1 (IL-1), tumor-necrosis
factor-alpha (TNF-α), IL-6, and IL-8.34,35 The initial reaction is usually the release of IL-1 and
TNF-α from activated macrophages and monocytes in the damaged tissues.34 This then
stimulates the production and release of more cytokines, in particular, IL-6, the main cytokine
responsible for inducing the systemic changes known as the acute phase response.34
Inflammation has been studied in relation to cognitive deficits in healthy young males and the
results showed a marked decrease in self-reported level of concentration and cognitive abilities,
as well as sleep impairment.34 A significant correlation has been found among inflammatory
markers, C-reactive protein (CRP) and interleukin-1 (IL-1) and neurocognitive decline in cardiac
surgery.4 Worthy of mention is the hypothesis that neuroinflammation is a common mechanism
between POCD and Alzheimer’s disease (AD) through the activation of microglial cells which
have been suggested to be very important for production of inflammatory mediators in response
to stressors.35,36 Blocking perioperative inflammatory response may play an important role in the
future in preventing POCD.34 Only a few studies are available in the literature about the
relationship between inflammatory biomarkers and the risk of POCD.
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Brain injury markers have also been studied as possible predictors of POCD assuming
that POCD can be a manifestation of transient or permanent cerebral injury.37 The most
commonly studied neuronal injury markers in POCD are S-100β protein and neuron-specific
enolase (NSE) and the results of these studies are still conflicting. Increased blood levels of NSE
and S-100β protein have been found in patients who sustained clinical neurological
complications after cardiac surgery.38 There are few studies that have been conducted to evaluate
the relationship between S-100β and NSE elevation and POCD especially after cardiac surgery.
Lili et al. tested the neuroinflammation theory in 80 patients 65 years or older undergoing
abdominal surgery who were randomized to receive ulinastatin (a drug widely used to treat acute
systemic inflammatory disorders) or to receive regular care in the control group.39 They
measured cognitive function seven days after surgery and they also measured the level of serum
IL-6, TNF-alpha, CRP, and S-100β before the surgery, at the end of the surgery, and on
postoperative days one to three.39 They found that significant decline in cognitive function
occurred in eight out of the nine cognitive tests they used.39 The ulinastatin group had a lower
incidence of POCD than the control group (2.5% versus 27.5%; p < 0.05).39 In the control group,
serum S-100β protein and IL-6 concentrations increased at the end of surgery and on
postoperative days one and two and the levels were significantly higher than those in the
ulinastatin group (p < 0.05). This recent study showed that the neuroinflammation theory might
play a role in the development of POCD and showed the potential for anti-inflammatory drugs to
protect against POCD in surgery. Also, the study showed that serum elevation of S-100β protein
can predict POCD.
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4. Postoperative delirium
POD has been generally linked with increased risk of long-term cognitive and functional
decline.15 POD is usually underestimated after surgery and is subjectively evaluated without the
use of validated and reliable tools to measure it. There has been much recent interest in studying
the potential relationship between experiencing POD and increased risk of long-term POCD.
Rudolph et al. studied a group of 1218 subjects 60 years old or above undergoing elective
noncardiac surgery and found an association between POD and POCD one week after surgery
(adjusted risk ratio 1.6, 95% CI: 1.1–2.1), but there was no association between them three
months after surgery.15 Hudetz et al. conducted a study in male older patients undergoing cardiac
surgery and included a nonsurgical control group that is similar in age and education level.40
They also found that POCD incidence was significantly greater in patients who had POD
delirium (89%) compared with those who did not (37%).40 The odds of developing POCD in
patients with POD were 14 times greater than in those who did not have POD.40

5. Postoperative Complications
There is a weak hypothesis that postoperative complications particularly infections and
respiratory depression may be risk factors for POCD. There are only a few studies that have
investigated the relationship between POCD and these factors. In the ISPOCD1 study, Moller et
al. found that postoperative infection and respiratory complications were associated with POCD
one week after the surgery.8 Further research is needed to prove or refute this theory. Abildstrom
et al. confirmed that postoperative infections (assessed until three months after surgery) were a
significant risk factor for POCD one to two years after noncardiac surgery, but they could not
find an association between respiratory complications and POCD.41
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C. PATIENT
1. Age
Age is the least controversial and strongest independent risk factor for POCD particularly
when we focus on long-term POCD which is usually assessed at least three months after surgery
to prevent any confusion with POD. Current POCD research is mainly conducted in older
patients since the risk of POCD is higher in this population. Moller et al. showed that age was
associated with both short- and long-term POCD in a group of 1218 older patients aged 60 years
or older undergoing major noncardiac surgery.8 Monk et al. included 1064 patients aged 18 years
or older and conducted a stratified analysis by age group and found that age was associated with
POCD three months after noncardiac surgery.2 The incidence of POCD was 5.7% in young,
5.6% in middle-aged, and 12.7% in older patients.42 The incidence of POCD was significantly
higher in older patients compared to their matched controls (p < 0.001).42 Also, Abildstrom et al.
confirmed that age was a significant risk factor for POCD one to two years after noncardiac
surgery.41

2. Cognitive Reserve
Cognitive reserve refers to a patient’s ability to buffer the effects of various insults that
may occur to the brain during surgery. However, cognitive reserve is subjective and cannot be
precisely measured, therefore surrogates of cognitive reserve have been suggested to include
education level, occupational attainment, and performance on tests of knowledge.43 There is
evidence that greater educational attainment is associated with a reduced relative risk of
developing Alzheimer's disease and this theory is suggested as one of the factors to be
considered when discussing the mechanisms and predictors of POCD.43 This theory suggests that
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patients with higher levels of education, as a hypothetical surrogate of cognitive reserve, may
have less deterioration in cognitive function than patients with lower education levels when they
are exposed to an equivalent insult. The association between lower occupational attainment and
incident dementia has also been discussed in a number of studies.43 In the ISPOCD1 study,
Moller et al. found that lower education level was associated with higher incidence of early
POCD at seven days after surgery but not with long-term POCD after three months.8 Monk et al.
confirmed this finding and also concluded that years of education was associated with POCD
three months after major noncardiac surgery.42 However, Abildstrom et al. conducted a study in
336 older patients and followed them for one to two years, but could not find a significant
relationship between education level and POCD.41 So, it seems that education level plays a role
in modulating the risk of POCD, but the cognitive reserve concept is probably more complex
than that and further research of intellectual measurement and its association with POCD is
needed.

3. Pre-existing Cognitive Impairment Before Surgery
Another theory of POCD suggests that patients who have pre-existing cognitive
impairment before surgery are at higher risk for POCD. This is particularly important to notice in
some patients with very mild, sometimes unobserved, forms of cognitive impairment who just
get pushed off of the cognitive cliff by the various stressors during surgery, accelerating their
cognitive decline and making it more prominent and sometimes permanent. Bekker et al. tested
this hypothesis when they retrospectively examined the records of 169 community-dwelling
older patients who were divided into two groups: mild cognitive impairment (MCI) and nonMCI groups. Patients with MCI had a greater decline in cognitive function than the non-MCI
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group.44 Silverstein et al. analyzed the data of the ISPOCD1 to determine if there was an
association between preoperative cognitive impairment (PCI) and POCD.45 They found that the
incidence of POCD was 19% in patients classified with PCI compared to 26.4% in non-PCI
patients one week after surgery (p = 0.19).45 At three months, the incidence of POCD was 15%
in patients classified with PCI compared to 9.5% in non-PCI patients (p = 0.23).45 There was no
significant association between preoperative cognitive impairment and POCD one week or three
months after surgery.45 The results of these two studies show that the evidence is still conflicting
about this theory, and more research is needed to determine if the presence and degree of
preoperative cognitive impairment can predict POCD.

4. Genetic Biomarkers
ApoE4 genotype has been implicated as a risk factor for AD, poor outcome after cerebral
injury, and accelerated cognitive decline with aging.46 There are three different ApoE isoforms
or alleles (ԑ2, ԑ3, ԑ4). The ApoE4 allele has been associated with increased risk of atherosclerosis
and AD.47 The link between genetic predisposition with the ApoE4 allele and cognitive decline
in the aging population is still debatable, since the ApoE4 allele has also been associated with
cerebrovascular diseases and atherosclerosis which can contribute to cognitive decline.47,48
Lelis et al. conducted a study in 87 older patients undergoing elective CABG surgery
who were genotyped for the presence of the ApoE4 allele.49 They found that 21.8% of study
subjects had POCD and carried the ApoE4 allele.49 They concluded that ApoE4 genotype was
significantly associated with early POCD one week after surgery (p = 0.04).49 However, this
study was limited by its small sample size, lack of control group to adjust for learning effects,
and the use of Mini-Mental State Examination (MMSE) solely to assess cognitive function
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which is inappropriate, as MMSE is only used to screen for dementia, and the current
recommendation for POCD assessment is to use a rigorous battery of tests that measures several
of the following domains: learning and memory, perception and attention, and executive
functioning.50 Silber et al. could not find an association between ApoeE4 and POCD in 282
patients undergoing CABG surgery when POCD was assessed three and twelve months after
surgery.51 The ApoE4 allele was present in 29.4% of total study patients.51 At three months after
surgery, the incidence of POCD in patients with and without the ApoE4 allele was 7.2% vs.
12.6% (p = 0.601), respectively.51 At twelve months after surgery, the incidence of POCD in
patients with and without the ApoE4 allele was 13.3% vs. 11.6% (p = 0.192), respectively.51
They concluded that POCD was not associated with ApoE4 in patients undergoing CABG
surgery.51 McDonagh et al. conducted a large study in which they recruited 394 patients over age
55 years undergoing elective major noncardiac surgery.37 They evaluated the incidence of POCD
in 350 patients who completed the study and found that the incidence was 54.3% at six weeks
after surgery and 46.1% at one year.37 There was no difference in the incidence between patients
with or without the APOE4 allele (56.6 vs. 52.6%; p = 0.58).37 The research about the
relationship between genetic predisposition with the Apoe4 allele and POCD is very promising,
however; there is still a need to accumulate enough evidence to confirm this hypothesis.37

5. Comorbidities
There is a hypothesis suggesting that certain patient comorbidities, especially endocrine
and vascular disorders, can contribute to the risk of POCD. This is particularly important to
study in older patients who usually have multiple comorbidities. Kadoi et al. studied 88 patients
undergoing elective CABG and they found that the incidence of POCD six months after the
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surgery was 27.3%.52 There was a significant association between POCD and the presence of
renal failure (OR = 2.8; 95% CI = 2.4 - 4.3; p < 0.01) and diabetes mellitus (OR = 1.8; 95% CI =
1.2 - 2.4; p < 0.01) six months after surgery.52 Hudetz et al. studied the association between
POCD and metabolic syndrome in a group of 60 older patients (30 with metabolic syndrome and
30 without it) after elective major noncardiac surgery and 30 nonsurgical controls.53 There was a
significant association between POCD one month after surgery and having the metabolic
syndrome. Patients with the metabolic syndrome had higher POCD incidence than those without
it (56.7 vs. 26.7%, respectively).54 There is a dearth of high quality research in this area, but it
seems that diabetes and vascular diseases could play a role in the risk of POCD.

II. SUMMARY
The etiology and pathophysiologic mechanisms of POCD are still elusive and POCD is
likely a multifactorial condition. There are three major theories in the literature that may explain
POCD: medication, surgery, and patient theories. The variables included in the medication
theory are type, duration, and depth of anesthesia, the use of highly anticholinergic or sedative
agents before, during, or after surgery, and the use of certain types of analgesic drugs especially
opioids postoperatively. The surgery theory suggests that factors associated with higher risk of
POCD include the type and duration of surgery, undesirable changes in intraoperative conditions
especially hyperthermia, hypoxemia, and hypotension, exposure of the brain to inflammation or
traumatic injury during surgery, postoperative delirium, and postoperative complications
especially infection and respiratory depression. The third theory is focused on the patient and it
suggests that factors such as older age, less cognitive reserve, pre-existing cognitive impairment
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before surgery, genetic predisposition with the ApoE4 allele, and patients’ comorbidities
especially vascular and endocrine diseases may be associated with higher risk of POCD.

III. DISCUSSION
There remains a gap in the literature about the incidence and risk factors for POCD in
older adults undergoing major noncardiac surgery. Several studies conducted to date did not use
enough neuropsychological tests that are sensitive to small changes in cognitive function to
evaluate POCD. Though there is a concern about the burden of lengthy cognitive testing on the
patient and the time constraints imposed by the clinical environment to conduct such tests, not
using enough tests to assess the various domains of cognitive function may result in missing
important cognitive deficits. Most of the studies did not evaluate patients’ depression and sleep
quality status before conducting cognitive tests to ensure they did not negatively affect patients’
performance on cognitive tests. Many study designs used a single group of patients and
examined the change in their performance over time without inclusion of a control group, which
is similar in age and level of education to the surgical group, to adjust for the learning effects that
occur from repeated administration of neuropsychological tests. This can underestimate the
incidence of POCD since patients may falsely improve on the tests instead of declining. In
conclusion, this research area suffers from several methodological issues that need to be
addressed. There is also a lack of studies evaluating the risk of POCD associated with
inflammatory biomarkers and genetic predisposition with the ApoE4 allele.
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CHAPTER 3: SIGNIFICANCE AND SPECIFIC AIMS

I. SIGNIFICANCE
POCD is not a new phenomenon and many studies have been conducted in this research
area. However, the incidence and potential risk factors of POCD are still elusive. This is mainly
due to the discrepancy in the definition of POCD in the literature and the use of measurement
tools to assess POCD that are not robust. For instance, many studies used the MMSE to
determine if patients had POCD, though MMSE is only validated for dementia screening and
should not be used as a neuropsychological tool to diagnose POCD. Also, many studies assessed
POCD either too early (e.g., one to seven days after surgery) or too late (e.g. one to two years or
longer after surgery). It is inappropriate to assess POCD too early in the postoperative period as
it usually gets confused with POD and the residual effects of the anesthesia and sedatives being
used during the recovery period. Also, assessing POCD too late can result in not being able to
capture the diagnosis and progress of POCD in the few months following surgery when
functional and cognitive decline can cause frustration to patients and overall decreased quality of
life. It is recommended to assess POCD several times after surgery at reasonable intervals (e.g.
one, three, six, and twelve months) because waiting too long for the first assessment can also
make it difficult to make the case that observed decline is specifically related to the surgery
without the interference of other variables such as age-associated memory loss or the progress of
underlying dementia.
Only a few studies acknowledged and adjusted for the fact that depression and poor sleep
quality can negatively affect patients’ performance on neurocognitive tests used for assessment
of POCD. Most POCD studies focused on patients undergoing cardiac surgery, particularly on-
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pump CABG surgery, and researchers’ attention has just recently shifted to studying POCD after
major noncardiac surgery. Only a few researchers have investigated the relationship between
pre-existing cognitive impairment before surgery and the risk of POCD development. Also, few
studies investigated the potential relationship between genetic predisposition with the ApoE4
allele or the release of several pro-inflammatory cytokines produced in response to surgical
stressors and the risk of POCD. Also, there are no studies that investigated the relationship
between home medications particularly those with highly anticholinergic or sedative effects and
the risk of POCD. There is a scarcity of studies about the effect of intraoperative conditions
particularly body temperature, blood pressure, and oxygen saturation and the risk of POCD.
Lastly but most importantly, many POCD studies did not include a nonsurgical control group to
adjust for the learning effects from repeated administration of neuropsychological tests which
can falsely underestimate the incidence of POCD.
These gaps and limitations of the current literature were the reasons to conduct our
exploratory study that is intended to determine the incidence and explore the largest number of
potential risk factors associated with long-term POCD. We used a robust computerized
neuropsychological battery that is valid, reliable, and sensitive to subtle changes in cognitive
function. The battery can also assess several important cognitive domains while minimizing
learning effects by providing alternate forms of the same test, meaning that no two presentations
of the same test are ever the same.
The outcomes of this study will help clinicians, patients, and their caregivers make better
informed decisions before they undergo major noncardiac surgery. With current advances in
surgery and anesthesia, older patients are less hesitant to undergo surgery, particularly
noncardiac procedures such as orthopedic or neurosurgery. The study seeks to provide additional
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evidence to guide these patients and their care providers in assessing the risk-benefit ratio of
undergoing this type of surgery. It may also help healthcare providers to use the least provocative
drugs and techniques without losing the benefits of surgery by identifying the risk factors for
POCD and if some of them may be modifiable.

II. SPECIFIC AIMS
The specific aims of this study were to:
a. Determine the incidence of POCD in older adults three months after elective major
noncardiac surgery.
b. Identify potential risk factors of POCD in older adults three months after elective
major noncardiac surgery.

III. SUMMARY
There is a gap in the literature about the incidence and risk factors of POCD in older
patients undergoing major noncardiac surgery. The current evidence is either flawed or not
sufficient to draw definitive conclusions. The specific aims of our study were to determine the
incidence and risk factors of long-term POCD in older adults undergoing major noncardiac
surgery. The outcomes of our study should help clinicians, patients, and their care providers
make better informed decisions when it comes to undergoing this type of surgery understanding
the incidence of POCD and who might be at risk of experiencing cognitive deterioration after
surgery.
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CHAPTER 4: METHODS

This is a prospective cohort study of patients aged 65 years and older who were
undergoing elective major noncardiac surgery at Virginia Commonwealth University Health
System (VCUHS). All patients provided written informed consent and the study has been
approved by VCU Institutional Review Board (IRB).

I. STUDY POPULATION
Patients were recruited during their visit to the pre-anesthesia clinic at VCUHS. Patients
had to be able to communicate in English and have the capacity to sign written informed consent.
Patients were excluded from the study if they were scheduled for another major surgery within
three months of the study surgery. Patients were also excluded if they scored less than 24 on the
MMSE-2 standard version during their initial interview. Patients were excluded if they had a
diagnosis or history of psychiatric disorders (e.g., schizophrenia and bipolar disorders),
neurodegenerative diseases (e.g., dementia), or metabolic diseases (e.g., diabetes) unless they
were under the observed care of a physician for the disorder, were taking their prescribed drug
regimen, and they appeared to the investigator team to be without evidence of cognitive
problems. Patients were excluded if they had a history of brain tumor or head trauma or if they
had any kind of motor dysfunction or physical disability (e.g., Parkinson’s disease), or any visual
or hearing impairment that would preclude computerized neurocognitive testing.
We also recruited a nonsurgical control group to adjust for the learning effects that may
occur from repeated administration of neuropsychological tests. The control group was
constituted of subjects aged 65 years or older recruited from an outpatient geriatric clinic at
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VCUHS during their regular checkup in addition to eligible individuals who accompanied study
patients to the pre-anesthesia clinic before surgery and were willing to serve as study controls.
We also included patients who originally joined the study in the patients group, but their surgery
was canceled or rescheduled for more than three months later. The control group had the same
inclusion and exclusion criteria as the study patients except that they were not having any major
surgery scheduled within three months of their involvement in the study.

II. TYPE OF SURGERY AND ANESTHESIA
Each study patient received either general anesthesia (inhaled and/or intravenous),
regional anesthesia (epidural, spinal, and/or nerve block ) with sedation, or a combination of
general and regional anesthesia based on a collaborative decision among surgeons, anesthesia
providers and each individual patient as is the current standard practice at VCUHS without any
influence from the study investigators.

III. OUTCOME ASSESSMENT
We used a computerized neurocognitive battery called CNS Vital Signs™ (CNSVS) to
assess cognitive function in both patients and controls. The assessment of cognitive function
using a computerized battery may be uniquely suited to early detection of cognitive changes in
the elderly.2 Computerized neurocognitive batteries have the advantages of covering a wider
range of abilities, minimizing floor and ceiling effects, standardizing the test administration, and
precisely recording accuracy and speed of response with a level of sensitivity not possible in
standard administrations with conventional paper-and-pencil testing.2 In addition, they are costand time-saving compared to conventional neurocognitive tests. They also allow appropriately
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trained personnel, other than only a neuropsychologist, to be able to administer these tests as
long as the interpretation of the results is done by the appropriate healthcare professional.2 CNS
Vital Signs™ neurocognitive battery has high validity and test-retest reliability, and it has been
evaluated in 1069 volunteers with age range of seven to ninety years old who were in good
health, without past or present psychiatric or neurological disorders, head injury, learning
disabilities, etc.; and were not taking any centrally-acting medications.3 Five tests were
administered to the study patients and controls as described below:
1. The Verbal Memory test is an adaptation of the Rey Auditory Verbal Learning test.3
Fifteen words are presented, one by one, and each stays on the screen for two seconds.
The subject is asked to remember these words, and then a longer list of thirty words is
presented that contains the first fifteen words the patients was asked to remember in a
randomly mixed manner. When the subject recognizes a word from the original shorter
list, he presses the spacebar on the keyboard. After this, the patient continues to complete
the remaining tests in the battery and just before the end of the testing session (about 20
minutes later), he is provided with another long list of thirty words that contains the
original fifteen words in a randomly mixed manner and he is asked again to recognize the
original fifteen words.
2. The Visual Memory which is based on the Rey Visual Design Learning test is exactly the
same as the Verbal Memory test except that fifteen and thirty geometric figures are
presented to the patient in the original and following lists, respectively, instead of words.
3. The Symbol Digit Coding test is a variant of the Wechsler Digit Symbol Substitution
test.3 The subject is given a training session to be familiar with the test before taking the
actual one. The test consists of serial presentations of screens, each of which contains a
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bank of eight symbols above and eight empty boxes below.3 The subject types in the
number that corresponds to the symbol that is highlighted.3 Only the digits from two
through nine are used to avoid the confusion between “1” and “I” on the keyboard.3 This
test lasts for 120 seconds and the goal is to type in as many correct numbers as one can in
this time frame.3
4. The Stroop Color test is a modification of the Stroop Color Word Interference test and it
has three parts.3 In the first part, the words RED, YELLOW, BLUE, and GREEN (all
printed in black) appear at random on the screen, and the subject presses the spacebar as
soon as he sees the word which generates a simple reaction time score.3 In the second
part, the words RED, YELLOW, BLUE and GREEN appear on the screen but printed in
color and the subject is asked to press the spacebar when the color of the word matches
what the word says.3 In the third part, the words RED, YELLOW, BLUE and GREEN
appear on the screen, printed in color and the subject is asked to press the spacebar when
the color of the word does not match what the word says.3
5. The Shifting-Attention test is based on Trails B and Wisconsin Card Sort test.3 Subjects
are instructed to match geometric objects either by shape or color.3 Three figures appear
on the screen, one on the top and two on the bottom.3 The top figure is either a square or a
circle and the bottom figures are a square and a circle.3 The figures are either red or blue;
the colors are mixed randomly and the subject is asked to match one of the bottom figures
to the top figure using a rule that is stated at the top and that keeps randomly changing at
each presentation (e.g., sometimes it will say ‘match color’ or ‘match’ shape in other
times).3 This goes on for 90 seconds and the goal is to make as many correct matches as
one can in the time allotted.3
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The tests embrace an appropriate span of cognitive domains (composite memory,
processing speed, executive function, reaction time, and cognitive flexibility) and have been
shown to be sensitive to most of the causes of mild cognitive impairment.3 The testing time
required to complete this battery is about 30 minutes. Because the presentation of stimuli in this
battery is randomized, no two presentations of a specific test are ever the same, making the
battery appropriate for repeated administration with minimal learning effect. Also, the battery
provides a brief practice before each test, except for the verbal and visual memory tests, to make
patients familiar and comfortable with test administration. The personnel who administered the
battery were extensively trained on neuropsychological test administration and relevant interview
techniques. Cognitive testing was conducted in a very quiet place and with no distractions to the
patient at all for the duration of the test. Patients were allowed to take breaks between the tests if
they felt exhausted, and to ask clarifying questions at any time.
We compared the level of computer use familiarity between the patient and control
groups to make sure it did not affect their performance differently on neurocognitive tests. We
asked subjects in both groups to self-rate their familiarity with general computer use as not
familiar at all, little familiar, familiar, very familiar, or expert with computer use. We then
categorized subjects into three groups (not familiar at all, little familiar/familiar, very
familiar/expert) for the purpose of statistical analysis.
Patients’ cognitive function was assessed preoperatively and three months after
postoperatively. We allowed flexibility of two weeks within which cognitive testing had to be
conducted in order to accommodate for patients’ schedules. Preoperative assessment of cognitive
function was conducted during patients’ visit to the pre-anesthesia clinic. Postoperative
assessment of cognitive function was conducted either at the hospital if patients had a follow-up

47

visits three months after surgery, or at patients’ residence if they did not have a follow-up visit
three months after surgery and they were not willing to come to the hospital for follow-up. The
same neurocognitive battery was used to assess cognitive function in the study controls at
baseline (time of recruitment) and three months later allowing flexibility of two weeks within
which cognitive testing had to be conducted in order to accommodate for controls’ schedules.
Baseline assessment of cognitive function was conducted during controls’ visit to the outpatient
geriatric clinic at VCUHS, or at the pre-anesthesia clinic if the control was accompanying a
study patient. The follow-up testing at three months was conducted either at the hospital or
residence of the subjects in the control group if they were not willing to come to the hospital for
follow-up testing.

IV. ASSESSMENT OF POSTOPERATIVE DELIRIUM (POD)
We evaluated study patients for the presence of POD 48 hours after their surgery while
they were still in the hospital. Our goal was to determine if patients who experienced POD after
postoperatively were more likely to experience POCD three months after surgery. We used the
Confusion Assessment Method (CAM) for this purpose.4 This test has been validated and it has
high sensitivity (94 – 100%) and specificity (90 – 95%) for detection of delirium.4 It is also
relatively easy and quick to administer, as it takes only five to ten minutes to complete.

V. DEPRESSION AND SLEEP QUALITY TESTING
It is well known that several factors including depression and poor sleep quality may
have a negative impact on a subject’s motivation, and can adversely affect his performance on
neuropsychological tests.5,6 For this reason, we evaluated our study subjects for the possibility of
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having depression and poor sleep quality before each cognitive testing session using the Geriatric
Depression Scale - Short-Form (GDS-SF) and the Pittsburgh Sleep Quality Index (PSQI),
respectively. The GDS-SF is composed of 15 yes/no questions and it has been compared to the
long-form 30 yes/no questions and showed to have equivalent sensitivity and specificity in older
adults.7 A score of 5 - 10 on the GDS-SF is suggestive of mild depression and a score of 11 - 15
is suggestive of severe depression. The PSQI takes about five minutes to administer and provides
a highly valid, reliable, and standardized measure of sleep quality for the previous month.8 It also
provides an index that is easy for researchers and clinicians to interpret and compare among
different patients.8 In patients with primary insomnia, PSQI has shown a test-retest reliability of
0.87, sensitivity of 89.6 – 98.7, and specificity of 84.4 – 86.5.8,9 A score of more than five on the
PSQI is suggestive of poor sleep quality, and the higher the score, the poorer patient’s sleep
quality is.
Our goal was to make sure we are only evaluating the change in cognitive function before
and three months after surgery in the surgical group with minimal or no interference from other
factors that could affect performance of study subjects on cognitive tests. First, we tested if there
was any significant change in the depression and sleep quality test scores from baseline till
follow-up within each study group, which could affect the performance of any of the two groups
differently on neurocognitive tests. Second, we compared the depression and sleep quality test
scores between the patient and control groups at baseline and follow-up to determine if there was
a difference between the two groups in depression status or sleep quality that could affect their
performance differently on neurocognitive tests.
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VI. DATA COLLECTION
Patients’ demographics, medical history, medication use, level of education, and
computer familiarity were documented before surgery by questioning the patients and reviewing
their medical charts. During the surgery, we collected information about the type, and duration of
anesthesia used. We also documented the type of surgery and the incidence of intraoperative
hypothermia, hypotension, and hypoxemia. For the purpose of this study, based on the views of
the anesthesia clinicians and surgeons involved in the study, we operationalized the definitions of
hypothermic, hypotensive, and hypoxemic events. A hypotensive event was defined as mean
blood pressure that is 20% lower than baseline. A hypothermic event was defined as body
temperature equal to or less than 36 ºC. A hypoxemic events was defined as oxygen saturation
less than 90%. After the surgery, we documented all postoperative medications taken by the
patient and any complications the patient may have experienced until hospital discharge. Study
data were collected and managed using the Research Electronic Data Capture (REDCap™) tool
hosted at VCU.1 REDCap™ is a secure, web-based application designed to support data capture
for research studies. Figure 1 summarizes the data collection process throughout the study from
baseline to follow-up.

VII. APOE GENOTYPING
On the day of surgery, we collected a 5-ml blood sample in a purple-top vacutainer just
before the induction of anesthesia from patients who opted to do this optional part of the study.
The sample was stored at -80 ºC until DNA purification has been done using the Spin-Column
protocol (DNeasy® Blood Kit, QIAGEN®). A 10 µl of diluted DNA per sample was transferred
into a 96-well plate. The DNA plate was placed into a thermal cycler and heated to 95 ºC for 5
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minutes. Once the heating process was completed, the DNA plate was placed on ice. DNA
amplification was performed using Taq polymerase kit (cat no. 18038-240, Invitrogen™). The
PCR product was checked on a 1% agarose gel electrophoresis. Restriction length fragment
polymorphism digestion was done by Hhal restriction enzyme. At the end of the incubation, the
reactions were terminated by the addition of bromophenol blue dye. The samples were then
loaded onto polyacrylamide gels. DNA ladder was added as reference and electrophoresis was
run. The gel was then soaked in a solution of ethidium bromide and viewed under UV light. A
computer-generated picture of the gel was recorded. Two independent researchers reviewed the
gel images and assigned an APOE genotype based on appropriate banding.

Figure 1. Summary of Data Collection Process from Baseline to Follow-up
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Neurocognitive Testing

Type/Duration of Anesthesia

Depression Evaluation

Sedative Medications

Sleep Quality Evaluation

Intraoperative Vital Signs
Perioperative Medications

Postoperative (Until Hospital Discharge)
POD Assessment

Three Months after Surgery

Postoperative Complications
Postoperative Medications

Neurocognitive Testing
Depression Evaluation
Sleep Quality Evaluation
Home Medications

Pre‐anesthesia
Clinic
Pre‐surgical Unit and
Operating Room
Patient’s Hospital
Room
Surgeon’s Office or
Patient’s Residence

51

VIII. INFLAMMATORY BIOMARKER ANALYSIS
On the day of surgery, we collected a 5-ml blood sample in a gold-top vacutainer just
before the induction of anesthesia from patients, who opted to do this optional part of the study,
to determine the preoperative level of CRP and evaluate if patients with preoperative heightened
inflammatory response may be at higher risk for POCD. The blood sample was allowed to clot
for 30 minutes after collection then it was centrifuged at 3500 RPM for 10 minutes at 4 ºC. The
CRP analysis was done on the serum using the polyethylene glycol (PEG) enhanced
immunoturbidimetric assay on Advia® 1800 analyzer.10 The method uses PEG to accelerate the
antigen-antibody interaction. The sample was allowed to react with a specific antiserum to form
a precipitate that was measured turbidimetrically at 340/694 nm. By constructing a standard
curve from the absorbances of standards, concentrations were determined. The reference range
for CRP level is 0.0 – 0.5 mg/dL and any value above that was considered high. The limit of
quantification for the test was 0.3 – 32.0 mg/dL. Estimates of precision, based on Clinical and
Laboratory Standards Institute (CLSI) recommendations, are consistent with typical
performance. The within run precision is less than 5% coefficient of variation (CV) and the
standard deviation (SD) is equal to or less than 1, and the total precision is less than 5% CV and
SD is equal to or less than 1.

IX. STATISTICAL ANALYSIS
Descriptive analysis of patients’ demographics, education level, computer familiarity, and
baseline MMSE-2 score was conducted. Continuous data were reported as mean and standard
deviation and/or range, and were compared using t-test or analysis of variance (ANOVA).
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Proportions were given as numbers and percentages were compared using Chi-square (2) or
Fischer’s exact test, when applicable.
The scores of GDS-SF and PSQI were compared at baseline and three months later
within each of the patient and control groups using paired t-test to determine if there has been
any significant change in depression status or sleep quality from baseline to follow-up that could
have affected their performance differently on cognitive tests. Next, the scores of depression and
sleep quality tests were compared between the two groups at baseline and follow-up using
ANOVA to determine if there was a significant difference between the two groups in their at
baseline or follow-up that could have interfered with their performance on cognitive tests.

A. Specific Aim #1
Determination of the incidence of POCD was done using the Z-Score method that was
originally used in both the ISPOCD1 and ISPOCD2 studies.11,12 A nonsurgical control group, that
is similar to the patients’ group in age, education level, and computer familiarity, was recruited
to adjust for potential learning or practice effects that may occur from repeated administration of
the cognitive tests. An individual Z-score was calculated for each test for each subject in the
surgical group by subtracting the mean score change for each test in the control group from the
score change in each patient in the surgical group from baseline to follow-up. The result was
then divided by the standard deviation for the mean score change in the control group. A
composite Z-score was also calculated by adding all individual Z-scores and dividing them by the
standard deviation of the mean sum of Z-scores in the control group. A patient was classified as
having POCD if he had an individual Z-score of less than -1.96 in two or more cognitive tests or
a composite Z-score of less than -1.96. This technique identifies patients with POCD by
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comparing the changes in test scores of an individual patient undergoing surgery with changes in
the test scores of the comparable control group over the same time interval.13

B. Specific Aim #2
A series of univariable logistic regression analyses using Chi-square were conducted at a
less conservative significance level of 0.25 to allow for the selection of potential predictors of
POCD without risking excluding some important variables that might play a role in the risk of
POCD in the final model. The univariable analysis included potential predictors of POCD from
the patient, surgery, and medication theories. The patient variables included age (65 – 74 years
old, 75 or older), gender (male, female), race (White, African-American or other), education
level (high school or less, more than high school), computer familiarity (not familiar at all, little
familiar or familiar, very familiar or expert), vascular and endocrine comorbidities (diabetes,
hypertension, hypothyroidism, hypercholesterolemia), and ApoE genotype (ApoE4, nonApoE4). The surgical variables included type of surgery (orthopedic surgery, neurosurgery), type
of anesthesia [general (inhaled, intravenous), regional (epidural, spinal, nerve block), a
combination of general and regional], duration of anesthesia (less than three hours, three hours or
more), use of nitrous oxide for general anesthesia (yes, no), use of desflurane for general
anesthesia (yes, no), use of sevoflurane for general anesthesia (yes, no), preoperative level of
CRP (normal or low, high), postoperative delirium (yes, no), hypotensive events (yes, no),
hypoxemic events (yes, no), and hypothermic events (yes, no). The medication variables
included the use of highly anticholinergic or sedative-hypnotic medications at home and
postoperatively (nonusers, users of one or more medications). The medication selection was
based on potential cognitive adverse outcomes of these medications in older adults as
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documented in the American Geriatrics Society 2012 updated Beers criteria for potentially
inappropriate medication use in older adults.14 We also evaluated the use of morphine (IV and
PCA), hydromorphone (IV and PCA), and oxycodone as postoperative analgesics (users,
nonusers) to determine if they were risk factors for POCD.
The model building process was done using backward stepwise logistic regression (pvalue was set at 0.25 and 0.10 for entering and leaving the model, respectively). The use of
backward stepwise regression was preferred due to the exploratory nature of our study and the
lack of definite knowledge of the potential predictors of POCD. Backward stepwise regression
begins with a model that includes all potential candidate variables of interest and minimizes the
risk of an important predictor not entering the model if the forward selection method was used.
Starting with all predictors, backward stepwise has the opportunity to identify and account for
any suppressor relationship among variables that can be found in the data. However, the
backward stepwise method has the disadvantage that it capitalizes on chance and the presence of
a large number of variables at once can lead to too many comparisons that may increase the risk
of ‘noise’ variables being included, which can decrease the predictive power of the model.
Results of the logistic regression analysis were reported as adjusted OR and 95% CI for
each variable in the multivariable logistic model using Firth’s method to accommodate for the
rarity of outcome and small sample size in our study. In normal logistic regression using the
maximum likelihood estimation method, we need at least five to ten events/outcomes in the
group with the smaller number of events for each predictor to be tested in the model. Firth’
method uses penalized maximum likelihood estimation method to reduce biased estimation in
case of rare events like in our study allowing us to relax the criteria of five to ten events per
tested predictor. We considered p-values less than 0.05 to be statistically significant, and p-
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values were two-sided for all statistical tests, when applicable. Data analysis was performed
using JMP® Pro 10.0.2 (SAS® Institute Inc., Cary, NC).
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CHAPTER 5: RESULTS

I. DEMOGRAPHICS AND BASELINE CHARACTERISTICS OF STUDY SUBJECTS
A total of 130 patients (surgical group) and 103 controls (nonsurgical group) were
approached for possible inclusion in the study, from which 96 patients and 93 controls consented
to participate in the study. After applying the inclusion and exclusion criteria and eliminating
those who were lost to follow-up, a total of 69 surgical and 54 nonsurgical were included in the
study and final analysis. Figures 1 and 2 show the recruitment process for the surgical and
nonsurgical groups, respectively.
The mean age for the surgical group was 71 years old and it ranged from 65 – 88 years
old. The mean age for the nonsurgical group was 73 years old and it ranged from 65 – 92. There
was a marginal difference between the two groups in age (p = 0.0428). White patients constituted
81.2% of the surgical group and 14.5% were African-American. In the nonsurgical group, 51.9%
were White and 48.1% were African-American. There was a difference between the two groups
in race (p < 0.0001). Females constituted 66.7% in the surgical group compared to 64.8% in the
nonsurgical group. There was no difference between the two groups in gender (p = 0.8298). The
two groups had similar education level (p = 0.1085), and most of the subjects in both groups had
an education level above high school (78.3% of surgical and 64.8% of nonsurgical study
subjects). There was no difference between the two groups in computer familiarity (p = 0.6821).
There was also no difference between the two groups in their baseline MMSE-2 score (p =
0.1235). Table 1 summarizes the demographics and baseline characteristics of both surgical and
nonsurgical groups.
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Figure 1. Recruitment Process for the Study Surgical Group

130 Approached

96 Consented

69 Included

6 Withdrew before
surgery

34 Refused

21 Excluded

5 Canceled
surgeries

6 Lost to follow-up

9 Had cognitive
impairment
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1 Did not speak
English

Figure 2. Recruitment Process for the Study Nonsurgical Group

103 Approached

93 Consented

54 Included

10 Refused

30 Excluded

30 Had cognitive
impairment
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9 Lost to follow-up

Table 1. Demographics and Baseline Characteristics of Surgical and Nonsurgical Groups

Variable

Age ± SD (range)
Gender (Females), %

Surgical

Nonsurgical

(N = 69)

(N = 54)

71 ± 5.4 (65 - 88)

73 ± 6.3 (65 - 92)

0.0428*

46 (66.7%)

35 (64.8%)

0.8298
<0.0001*

Race, %
White

56 (81.2%)

28 (51.9%)

African-American

10 (14.5%)

26 (48.1%)

3 (4.3%)

0 (0.0%)

Other

0.1085

Education Level, %
High school or less

15 (21.7%)

19 (35.2%)

More than high school

54 (78.3%)

35 (64.8%)
0.6821

Computer Familiarity, %
Not familiar at all

9 (13%)

10 (18.5%)

Little familiar or familiar

37 (53.6%)

26 (48.1%)

Very familiar or expert

23 (33.3%)

18 (33.3%)

28 ± 1.4

28 ± 1.7

MMSE-2 Score ± SD

p-value

*p-value < 0.05
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0.1235

II. DEPRESSION STATUS AND SLEEP QUALITY AT BASELINE AND FOLLOW-UP
First, we compared the depression status and sleep quality score change from baseline to
follow-up within each of the surgical and nonsurgical groups using paired t-test to determine if
there has been any change in depression or sleep quality within each group from baseline to
follow-up. We wanted to rule out the possibility that a change in depression status or sleep
quality within any of the two groups could have affected that group’s performance on
neurocognitive tests differently from baseline to follow-up. Table 2 summarizes the mean and
follow-up depression scores and the differences in these scores between the two testing sessions
within each group. There was no difference in depression status between the two testing sessions
within the surgical or nonsurgical group (t = 0.67, p = 0.51; t = -0.99, p = 0.33, respectively).
Table 3 summarizes the mean and follow-up sleep quality scores and the differences experienced
in these scores from baseline to follow-up within each group. There was no difference in sleep
quality from baseline to follow-up within the surgical or nonsurgical group (t = 0.57, p = 0.57; t
= 0.21, p = 0.83, respectively). These results show that there was no significant change in
depression status or sleep quality within the surgical or nonsurgical groups that could have
affected their performance on cognitive testing at baseline and the three-month follow-up.
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Table 2. Comparison of Depression Status scores within Surgical and Nonsurgical Groups at
Baseline and Three-Month Follow-up as Measured by GDS-SF
Group

Time

N

Mean

SD

Score

Surgical

Nonsurgical

Lower

Upper

95% CI

95% CI

Baseline

69

2.1

2.2

1.5

2.6

Follow-up

69

2.2

2.6

1.6

2.8

Difference

69

0.1

1.8

-0.3

0.6

Baseline

54

2.6

2.7

1.9

3.3

Follow-up

54

2.3

2.9

1.5

3.1

Difference

54

-0.3

2.2

-0.9

0.3
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Table 3. Comparison of Sleep Quality within Surgical and Nonsurgical Groups at Baseline and
Three-Month Follow-up as Measured by PSQI
Group

Time

N

Mean

SD

Score

Surgical

Nonsurgical

Lower

Upper

95% CI

95% CI

Baseline

69

6.8

3.7

5.9

7.7

Follow-up

69

7.0

3.8

6.1

7.9

Difference

69

0.2

3.0

-0.5

0.9

Baseline

54

6.3

4.0

5.2

7.4

Follow-up

54

6.4

3.9

5.3

7.4

Difference

54

0.1

2.6

-0.6

0.8
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Second, we compared depression status and sleep quality scores between the surgical and
nonsurgical groups at baseline and follow-up using ANOVA to determine if they were different
in depression status or sleep quality at baseline or follow-up. Table 4 summarizes the mean
GDS-SF scores for both the surgical and nonsurgical groups at baseline and follow-up. ANOVA
test showed no difference in depression status between the two groups at baseline (F (1, 121) =
1.37, p = 0.2447) or after three months (F (1, 121) = 0.03, p = 0.8738). Table 5 summarizes the
mean PSQI scores for both the surgical and nonsurgical groups at baseline and follow-up.
ANOVA test showed no difference in sleep quality scores between the two groups at baseline (F
(1, 121) = 0.45, p = 0.5059) or after three months (F (1, 121) = 0.73, p = 0.3954). These results
show that there was no significant difference in depression status or sleep quality between the
surgical or nonsurgical groups at either baseline or follow-up that could have affected their
performance differently on cognitive testing.
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Table 4. Comparison of Depression Status between Surgical and Nonsurgical at Baseline and
Follow-up as Measured by GDS-SF
Time

Group

N

Mean

SD

Score

Lower

Upper

95% CI

95% CI

Surgical

69

2.1

2.2

1.5

2.7

Nonsurgical

54

2.6

2.7

1.9

3.3

Surgical

69

2.2

2.6

1.6

2.9

Nonsurgical

54

2.3

2.9

1.6

3.0

Baseline

Follow-up
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Table 5. Comparison of Sleep Quality between Surgical and Nonsurgical at Baseline and Followup as Measured by PSQI
Time

Group

N

Mean

SD

Score

Lower

Upper

95% CI

95% CI

Surgical

69

6.8

3.7

5.9

7.7

Nonsurgical

54

6.3

4.0

5.3

7.4

Surgical

69

7.0

3.8

6.1

7.9

Nonsurgical

54

6.4

3.9

5.4

7.4

Baseline

Follow-up
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III. INCIDENCE AND RISK FACTORS OF POCD
A patient in the surgical group was classified as having POCD if he had an individual Zscore of less than -1.96 in two or more of the cognitive tests, or a composite Z-score of less than 1.96. Based on this method, a total of 11 (15.9%) patients in the surgical group were classified as
having POCD. We evaluated the association between POCD and several variables at a preset
significance level of 0.25 to screen for potential predictors of POCD to be entered into the final
logistic regression model with a significance level of 0.05. We chose the stepwise backward
logistic regression method to build the model due to the exploratory nature of this study and lack
of a specific hypothesis. Table 6 shows the results of the univariable analysis of potential risk
factors for POCD and the distribution of patients with POCD across the levels of each predictor.
Only one patient did not opt to provide blood samples for the purpose of CRP and ApoE4
analysis, which was an optional part of the study that patients could opt out of it. Among the
patients who were using anticholinergic drugs before surgery, four were using diphenhydramine,
four were using loratadine, three were using meclizine, two were using promethazine, one was
using cyclobenzaprine, one was using methocarbamol, one was using tizanidine, one was using
solifenacin, and one was using scopolamine. Among the patients who were using sedativehypnotic drugs before surgery, six were using zolpidem, three were using clonazepam, two were
using diazepam, two were using alprazolam, one was using lorazepam, and one was using
flurazepam.
In the surgical group, 13 patients received general anesthesia and 48 received regional
anesthesia, and eight patients received combined general and regional anesthesia. Among those
who received general anesthesia, 20 patients received sevoflurane, two patients received
sevoflurane, and seven patients received nitrous oxide.
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Table 6. Results of Univariable Analysis for Initial Screening of Potential Risk Factors for POCD

Variable

N = 69

POCD

No POCD

p-value

65 – 74 years old

55

10 (18.2%)

45 (81.8%)

0.4397

≥ 75 years old

14

1 (7.1%)

1 (92.9%)

Male

23

2 (8.7%)

21 (91.3%)

Female

46

9 (19.6%)

37 (80.4%)

White

56

9 (16.1%)

47 (83.9%)

African-American or other

13

2 (15.4%)

11 (84.6%)

High school or less

15

4 (26.7%)

11 (7.3%)

More than high school

54

7 (13.0%)

47 (87.0%)

Not familiar at all

9

1 (11.1%)

8 (88.9%)

Little familiar or familiar

37

6 (16.2%)

31 (83.8%)

Very familiar or expert

23

4 (17.4%)

19 (82.6%)

No

57

9 (15.8%)

48 (84.2%)

Yes

12

2 (16.7%)

10 (83.3%)

No

31

6 (19.4%)

25 (80.6%)

Yes

38

5 (13.2%)

33 (86.8%)

No

64

10 (15.6%)

54 (84.4%)

Yes

5

1 (20.0%)

4 (80.0%)

Age

Gender
0.3139

Race
1.000

Education Level
0.2374

Computer Familiarity
1.000

Diabetes
1.000

Hypertension
0.5251

Hypothyroidism
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1.000

Hypercholesterolemia
No

57

9 (15.8%)

48 (84.2%)

Yes

12

2 (16.7%)

10 (83.3%)

Non-ApoE4

54

6 (11.1%)

48 (88.9%)

ApoE4

14

5 (35.7%)

9 (64.3%)

Orthopedic Surgery

61

8 (13.1%)

53 (86.9%)

Neurosurgery

8

3 (37.5%)

5 (62.5%)

General anesthesia

13

3 (23.1%)

10 (76.9%)

Regional anesthesia

48

4 (8.3%)

44 (91.7%)

Combined general and regional anesthesia

8

4 (50.0%)

4 (50.0%)

Less than three hours

23

6 (26.1%)

17 (73.9%)

Three or more hours

46

5 (10.9%)

41 (89.1%)

No

62

8 (12.9%)

54 (87.1%)

Yes

7

3 (42.9%)

4 (57.1%)

No

67

10 (14.9%)

57 (85.1%)

Yes

2

1 (50.0%)

1 (50.0%)

No

49

5 (10.2%)

44 (89.8%)

Yes

20

6 (30.0%)

14 (70.0%)

Normal or low

50

7 (14.0%)

43 (86.0%)

High

18

3 (16.7%)

15 (83.3%)

1.000

ApoE4 Genotype#
0.0407

Type of Surgery
0.1090

Type of Anesthesia
0.0091

Duration of Anesthesia
0.1611

Use of Nitrous Oxide for General Anesthesia
0.0751

Use of Desflurane for General Anesthesia
0.2954

Use of Sevoflurane for General Anesthesia
0.0669

CRP Level#

71

0.7175

Postoperative Delirium^
No

44

5 (11.4%)

39 (88.6%)

Yes

10

2 (20.0%)

8 (80.0%)

No

7

1 (14.3%)

6 (85.7%)

Yes
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10 (16.1%)

52 (83.9%)

No

63

11 (17.5%)

52 (82.5%)

Yes

6

0 (0.0%)

6 (100.0%)

No

10

3 (30.0%)

7 (70.0%)

Yes
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8 (13.6%)

51 (86.4%)

Nonusers

44

4 (9.1%)

40 (90.9%)

Users

25

7 (28.0%)

18 (72.0%)

Nonusers

37

4 (10.8%)

33 (89.2%)

Users

32

7 (21.9%)

25 (78.1%)

No
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9 (13.6%)

57 (86.4%)

Yes

3

2 (66.7%)

1 (33.7%)

No

29

5 (17.2%)

24 (82.8%)

Yes

40

6 (15.0%)

34 (85.0%)

14

3 (21.4%)

11 (78.6%)

0.6014

Hypotensive Events
1.000

Hypoxemic Events
0.5795

Hypothermic Events
0.1920

Use of ≥ 1 Anticholinergic or Sedative-Hypnotic
Drugs at Home Prior to Surgery
0.0830

Use of ≥ 1 Anticholinergic or Sedative-Hypnotic
Drugs after Surgery
0.2106

Use of Morphine for Postoperative Pain
0.0640

Use of Hydromorphone for Postoperative Pain
1.000

Use of Oxycodone for Postoperative Pain
No
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0.6827

Yes

55

8 (14.6%)

47 (85.4%)

*p-value < 0.25
#

One patient refused to provide blood samples for testing of genetic and inflammatory biomarkers

^

Fifteen patients were discharged earlier than the time for assessment of postoperative delirium
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The variables that were included in the final model were ApoE4 genotype, use of one or
more highly anticholinergic or sedative-hypnotic medications at home, and the use of
sevoflurane for anesthesia. There was no evidence of lack of fit of the final model for the
included variables which was tested using Hosmer-Lemeshow goodness-of-fit test (p = 0.9550).
Table 6 presents the results of the multivariable logistic regression analysis with adjusted OR,
95% CI, and p-values for the predictors that were entered in the final model and also the
incidence of POCD at different levels of each variable.
The association of ApoE4 genotype with POCD was such that patients in the surgical
group who had the ApoE4 gene were more likely to have POCD three months after the surgery
as compared to patients who did not have the ApoE4 gene (OR = 4.74, 95% CI = 1.09 – 22.19, p
= 0.0371). Patients in the surgical group who were using one or more highly anticholinergic or
sedative-hypnotic drugs at home before surgery were more likely to have POCD three months
after the surgery when compared to patients who were not taking any drug with high
anticholinergic or sedative-hypnotic characteristics (OR = 5.64, 95% CI = 1.35 – 30.22, p =
0.0137). Patients who were administered sevoflurane for anesthesia were more likely to have
POCD three months after surgery than patients who did not receive it (OR = 6.43, 95% CI = 1.49
– 34.66, p = 0.0102).
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Table 7. Results of Multivariable Logistic Regression showing Factors Associated with POCD

Variable

N

POCD

No POCD

Adjusted OR

p-value

(95% CI)
ApoE4 Genotype
Non-ApoE4

54

6 (11.1%)

48 (88.9%)

1.00

ApoE4

14

5 (35.7%)

9 (64.3%)

4.74 (1.09 – 22.19)

Nonusers

44

4 (9.1%)

40 (90.9%)

1.00

Users

25

7 (28.0%)

18 (72.0%)

5.64 (1.35 – 30.22)

No

49

5 (10.2%)

44 (89.8%)

1.00

Yes

20

6 (30.0%)

14 (70.0%)

6.43 (1.49 – 34.66)

0.0371*

Use of ≥ 1 Anticholinergic/Sedative-Hypnotic
Drugs at Home Prior to Surgery
0.0137*

Use of Sevoflurane for Anesthesia

*p-value < 0.05
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0.0102*

IV. SUMMARY
The study included 69 patients aged 65 years and older who underwent elective major
noncardiac surgery (orthopedic surgery and neurosurgery) and 54 nonsurgical controls to adjust
for the learning effects from repeated administration of the neurocognitive tests. The surgical and
nonsurgical groups were similar in gender, education level, computer use familiarity, and
baseline MMSE-2 score. The two groups were different in age marginally in favor of the
nonsurgical group, and in race as the surgical group had larger proportion of White subjects.
There was no difference between the two groups in depression status and sleep quality scores at
baseline or follow-up. Within each group, there was no difference in depression status and sleep
quality scores between baseline and follow-up. Using the Z-score method, we identified 11
(15.9%) patients with POCD in the surgical group. Multivariable logistic regression analysis
using Firth’s method showed that carrying the ApoE4 allele (at least one allele), using one or
more highly anticholinergic or sedative-hypnotic medications at home prior to surgery, and
receiving sevoflurane for anesthesia were predictors of the development of POCD.
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CHAPTER 6: DISCUSSION

I. INCIDENCE OF POCD
The results of this study showed that about 16% of study subjects were identified with
POCD three months after elective major noncardiac surgery. A major difficulty of all POCD
studies is the comparability of POCD incidence between different studies, as this depends largely
on how POCD was defined and what was considered as ‘sufficient’ decline in cognitive function
after surgery in each study. Also, this varies by the time of postoperative assessment of cognitive
function. Several studies overestimated the incidence of POCD by evaluating it during the first
week after surgery when the patient is still having pain, in recovery from anesthesia, and under
the influence of several postoperative analgesics. The incidence will also depends on whether the
study has a control group to adjust for learning effects that occur from repeated administration of
neurocognitive tests.
In our study, we used the most stringent definition of POCD that is dependent on the Zscore method originally used by the ISPOCD group, and we also used a control group to adjust
for learning effects.1 However, the use of POCD as a dichotomous variable (yes or no) has its
limitations as well particularly it decreases the power of the study as compared to defining it as a
continuous variable by assessing mean score change in study subjects. However, the use of mean
score change in POCD studies is not recommended because learning effects are disregarded, and
the individual change is thereby not assessed. Instead, the definition of POCD should be based
on comparing preoperative with postoperative test results for each patient. The Z-score method
provides us with information about the expected improvement over time in the surgical group by
looking at the change in the nonsurgical control group. This definition corrects for this learning
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effect and eliminates the risk that a true deterioration in cognitive function may be overlooked in
the surgical group.
Newman et al. conducted a meta-analysis of POCD studies in noncardiac surgery until
December 2005 showing that the incidence of POCD was 6.2% - 56% after major noncardiac
surgery when assessed 22 days and up to six months after surgery.2 When ignoring one of the
studies included in the meta-analysis with unexpectedly very high incidence, the incidence of
POCD was between 6.2% - 9.4%.2 The incidence of POCD in our study is in agreement with the
incidence reported in the first ISPOCD study which was about 10%.1 Monk et al. conducted a
study in 1064 patients, 308 of which were in a group aged 60 years or older.3 Three months after
surgery, the incidence of POCD was 12.7% in this group of older patients, which is comparable
to the percentage of POCD in our study.3 Koch et al. reported a POCD incidence of 45% three
months after surgery in a group of 24 patients aged 65 years or older who underwent elective
knee or hip replacement.4 The incidence reported in this study is very high compared to our
study. However, though this study used robust measures for neuropsychological testing, their
definition of POCD was very arbitrary and is not the currently acceptable definition in POCD
research that was established by the first ISPOCD study. Koch et al. used a definition of at least
20% decline from baseline in two or more tests which could result in the overestimated incidence
of POCD. Evered et al. conducted a very recent study in 644 patients, 157 of which were 55
years and older, who underwent total hip joint replacement.5 They reported a POCD incidence of
16% three months after surgery which is also in agreement of the incidence in our study.5 Deo et
al. conducted a study in two groups of patients undergoing knee replacement with age ranging
from 43 to 82 years old, and they compared the incidence of POCD in the two groups using two
different surgery techniques.6 They found a similar POCD incidence of about 30% six months
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after surgery in both groups.6 This high incidence of POCD in this study may be also be a result
of using a less stringent approach in diagnosing POCD (0.5 SD decline in at least three cognitive
tests).6
Our study used a robust computerized neurocognitive battery that is valid and reliable,
and is designed specifically to evaluate subtle changes in cognitive function over time. The
battery measures several cognitive domains that were recommended by consensus guidelines for
evaluation of POCD.7 The battery was also validated in volunteers with several age groups
ranging from seven to ninety years old, which includes the age range for our study patients.8 We
used a control group that is similar to the surgical patients in age, education level, and computer
use familiarity along with the use of parallel forms in the neurocognitive battery to prevent or
minimize learning effects to the most degree possible. In addition to that, we used the currently
established Z-score method for identifying patients with POCD. This definition that was
originally used in the first ISPOCD study is robust and it also adjusts for any learning effects
from repeated administration of the cognitive tests to provide a reasonably accurate estimate of
POCD incidence.
It is also very important to note that we acknowledged the fact that depression and poor
sleep quality can negatively affect performance on neuropsychological testing, and we evaluated
the depression status and sleep quality for the surgical and nonsurgical groups at baseline and
follow-up to make sure there was no variability in depression status or sleep quality within and
between the two groups that could have affected their performance differently on cognitive tests,
and consequently the incidence of POCD. Our decision to evaluate the incidence of POCD three
months after surgery was based on the overestimated incidence observed in several studies that
evaluated POCD too soon after surgery and reported an inflated incidence of POCD. Even if a
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the high incidence of POCD reported in some studies shortly after surgery represents a true
deterioration, we chose to evaluate long-term cognitive outcomes which is more important to
patients and their caregivers than changes that nay occur immediately in the short period after
surgery and become reversible soon after hospital discharge. The incidence reported in our study
supports the fact that POCD does exist in older adults three months after major elective
noncardiac surgery with an incidence of about 16% when assessed using robust
neuropsychological tests and defined using the Z-score method with the involvement of a
nonsurgical control group to adjust for the learning effects.

II. RISK FACTORS FOR POCD
The multivariable analysis in our study showed that risk factors for POCD were carrying
the ApoE4 allele, using one or more drugs with highly anticholinergic or sedative-hypnotic
properties at home prior to surgery, and receiving sevoflurane for anesthesia. The current
evidence in the literature about the association between these risk factors and POCD is still
lacking and conflicting.
In our study, the percentage of patients identified with POCD who had the ApoE4 allele
was 35.7% compared to 11.3% who did not have the allele. Carrying the ApoE4 allele was
associated with POCD three months after major noncardiac surgery in our study. This is not in
agreement with the investigation by Abildstrom et al. who conducted a multicenter study in a
total of 976 patients aged 40 years and older undergoing noncardiac surgery and could not find a
difference in the incidence of POCD three months after surgery in patients with and without the
ApoE4 allele (ApoE4 = 10.3%, non-ApoE4 = 8.4%; p = 0.40).9 However, the statistical power of
this study was limited because of the lower incidence of POCD than expected and they also
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included patients who are much younger than our patient group.9 The same finding was reported
by McDonagh et al. who conducted a study in 394 patients older than 55 years old who
underwent major noncardiac surgery.10 When they evaluated POCD one year after surgery in 291
subjects, they could not find an association between ApoE4 genotype and POCD (ApoE4 =
45.9%, non-APOE4 = 46.3%; p = 0.95).10 However, this study had an exaggerated incidence of
POCD due to using a more liberal arbitrary definition of POCD. A recent study by Cai et al.
showed an association of POCD with ApoE4 genotype three days after noncardiac surgery.11
However, they used MMSE in identifying patients with POCD, which is no longer an accepted
method to diagnose POCD or evaluate any changes in cognitive function in general. MMSE is
only a screening instrument for dementia and, alone, cannot yield a diagnosis of dementia or
cognitive problems.12 The mechanism by which ApoE4 may cause detrimental cognitive
outcomes is still unclear.10 Potential etiologies include the specific effects on cerebral blood
flow, altered responses to neuronal injury, cerebral metabolic decline, and increased cerebral
microemboli secondary to increased atheroma burden.10 Also, there is support from several
studies that ApoE4 may be linked to the inflammatory response to injury that may occur during
surgery.10 ApoE4 can modulate this response by modifying glial activation, nitric oxide
production, inflammatory cytokine production, and magnitude of cerebral edema.10 The
association of ApoE4 gene with both POCD and AD can suggest that these two conditions may
share similar mechanisms through β-amyloid and tau phosphorylation formation.13
Our study is the first to investigate the association between using highly anticholinergic
or sedative-hypnotic drugs at home prior to surgery and the risk of POCD three months after
major noncardiac surgery. We only considered highly anticholinergic and sedative-hypnotic
medications that have been included in the 2012 American Geriatrics Society updated Beers
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criteria for potentially inappropriate medication use in older adults, as they are supported with
strong evidence to cause harmful cognitive outcomes in older adults.14 Also, the anticholinergic
drugs included in the list are only those with strong anticholinergic properties compiled from the
Anticholinergic Risk Scale, Anticholinergic Drug Scale, and Anticholinergic Burden Scale
which makes this list comprehensive.14 Highly anticholinergic drugs have been known for a long
time to have negative cognitive outcomes especially in the older adult population.15-17 Carrière et
al. studied a population-based cohort of 4128 women and 2784 men recruited from three French
cities who had their cognitive function, clinical diagnosis of dementia, and anticholinergic
evaluated at baseline, two, and four years later.18 The study found that older adults who were
taking anticholinergic drugs were at increased risk for cognitive decline and dementia, and
discontinuing anticholinergic drugs was associated with a decreased risk.18 Interestingly, there
was an interaction between the use of anticholinergic drugs in women and carrying the ApoE4
allele exposing patients with both to higher risk of cognitive dysfunction and dementia.18 Cai et
al. conducted a retrospective cohort study with one-year follow-up of cognitive function in 3690
older adults finding that the odds ratio for having a diagnosis of mild cognitive impairment
(MCI) was 2.73 (1.27–5.87) among older adults who were exposed to three or more possible
anticholinergic drugs for at least 90 days.19 Also, the long-term use of sedative-hypnotics,
particularly benzodiazepines, is a risk factor for increased cognitive decline in older adults.20,21
The cumulative burden of using these drugs at home prior to surgery can put the patients
at higher risk to the insult from the surgery and anesthesia, which may expedite the progression
of cognitive deterioration and make it more prominent few months after surgery. Our study
showed that patients who were using at least one highly anticholinergic or sedative-hypnotic
medications at home before surgery were at higher risk for POCD three months after surgery.
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The reason we categorized the use of anticholinergic and sedative medications into only two
groups (nonuse, and using one or more medications of this group) is that, with the exception of
one patient who was using three medications and another who was using four medications of this
group, all other patients were either nonusers or users of only one anticholinergic or sedativehypnotic medications.
There is a growing interest in the involvement of individual anesthetic agents in the
etiology of POCD. In our study, we compared the risk of POCD associated with the use of each
individual anesthetic agent in study patients. The results showed that the use of sevoflurane for
anesthesia was associated with higher risk of POCD three months after major noncardiac
surgery. The relationship between sevoflurane and POCD or cognitive decline in general is still
debatable. A study by Dong et al. showed that sevoflurane can induce apoptosis and increase βamyloid protein levels in mice which suggests that sevoflurane may promote AD
neuropathogenesis.22 Le Freche et al. reached a similar conclusion when they demonstrated that
sevoflurane exposure was associated with increased tau-phosphorylation and spatial memory
deficits in mice one month after surgery.23 In this study, cognitive deterioration was transient at
the first exposure to sevoflurane, but it became permanent with repeated exposure to the
anesthetic agent.23 Liu et al. conducted a prospective, randomized parallel-group study in 180
patients aged 65 to 75 years old with amnestic mild cognitive impairment, a subtype of mild
cognitive impairment in which memory loss is the predominant symptom, who were randomly
assigned to a sevoflurane, propofol or lidocaine epidural anesthesia group (n = 60 per group)
during spinal surgery.24 They assessed patients’ cognitive function before and two years after
surgery and obtained a cerebrospinal fluid sample by lumbar puncture from patients before the
end of the surgery.24 They found that the number of cases who had progressive mild cognitive
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impairment was greater in the sevoflurane group, and not the propofol or lidocaine groups, than
in the control group.24 Patients who developed progressive amnestic mild cognitive impairment
had increased total tau and increased phosphorylated tau levels compared with those with stable
mild cognitive impairment and the control group.24 On the other hand, sevoflurane has been
suggested to have a protective effects on long-term cognitive function of Wistar rats by
suppressing the inflammatory responses that occur during surgery.25 However, it is still unknown
if these findings can be applied to humans, and whether the duration of anesthesia can play a role
in changing the neuroprotective effect of sevoflurane during surgery to a detrimental effect on
cognitive function with extended exposure. Kadoi et al. conducted a retrospective study on 109
patients to test whether sevoflurane anesthesia had any ameliorative effects on POCD after
CABG surgery.26 However, they could not find a significant association between POCD six
months after surgery and the use of sevoflurane.26 These studies show that most of the research
about the relationship between sevoflurane and the risk of cognitive deterioration conducted in
humans reported either a protective effect or no difference in the risk between sevoflurane and
other anesthetics agents. However, recent studies in animals showed significant and dosedependent deterioration of cognitive function with the use of sevoflurane. This warrants a need
for further studies to compare the risk of POCD associated with the use of sevoflurane and other
anesthetic agents in humans at variable doses and duration of exposure, and to confirm the
possible tau phosphorylation mechanism by which sevoflurane might be causing cognitive
deterioration after surgery.

III. STUDY LIMITATIONS
A major limitation of all studies investigating the incidence and risk factors of POCD is
that there are major differences in research methodologies, including the neurocognitive batteries
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used, the time interval between preoperative and postoperative assessment, and the definition and
statistical methods used to identify patients with POCD. We used a robust study design that is
consistent with the most recent guidelines and methodology of large studies particularly the
ISPOCD studies allowing us to compare our findings with the findings of other well-designed
studies. However, our study was limited by the small sample size due to the prospective nature of
the study and the limited time and funding we had to recruit enough subjects. Despite the small
sample size, we could still find a POCD incidence of 16% in our study subjects and this
incidence is in agreement with current investigations of POCD after noncardiac surgery with
robust methodology.
One of the limitations of observational studies is that they can only identify associations,
and not causality, between independent variables and the outcome of interest. Due to the
observational nature of our study, it is possible that the association we found between POCD
three months after major noncardiac surgery and carrying the ApoE4 allele, using at least one
highly anticholinergic or sedative-hypnotic drug prior to surgery, and receiving sevoflurane for
anesthesia was due to chance. An alternative explanation of the results or other underlying
causes for POCD may exist. In order to confirm a cause-and-effect relationship between these
risk factors and long-term POCD, randomized-controlled trials should be conducted.
We had to conduct some of the follow-up cognitive testing sessions for patients in both
surgical and nonsurgical groups at their residence if they were not willing to come back to the
hospital. Theoretically, this could have affected the results of the study by performing the followup cognitive testing at two different environments assuming that the hospital environment may
be more stressful to study subjects compared to their own residence. However, we always
recommended that patients do the follow-up testing at the hospital and we did not choose which
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patients do the follow-up testing at their residence, and it was randomly based on the willingness
of patients to come back to the hospital. However, we did not want to risk losing patients at
follow-up in addition to the fact that cognitive testing done at the hospital was conducted in a
very quiet private room with no distractions at all which may simulate patient’s home
environment.
Pain and anxiety can negatively affect performance of patients on neurocognitive testing
and may cause them to be less motivated or focused on the test. Patients in the surgical group
probably had pain and anxiety before the surgery during baseline cognitive testing. The level of
pain and anxiety could have changed, probably decreased, by the time of follow-up testing three
month after surgery which could have led to improvement of their performance on the tests. We
did not assess the level of pain or anxiety at baseline or follow-up, and we do not know if this
had an effect on the results of cognitive tests. We thought it would be too much burden and timeconsuming to assess pain and anxiety in addition to depression and sleep quality before each
testing session. Conducting an extensive battery of tests can discourage many patients from
participation in research. If not evaluating pain and anxiety before each testing session has
caused any error, it would have underestimated the incidence of POCD in our study, because
patients would be expected to have improved performance on cognitive tests.
A large percentage of subjects in the patient and control groups refused to participate in
the study. We do not have information about those who refused to participate since they did not
sign the consent form. However, it is concerning whether the demographics and characteristics
of subjects who did not participate in the study might be different from those who were included
in the study. It is often the very old and more fragile patients who refuse to participate in studies
like this particularly if they might be concerned about their cognitive function and they prefer not
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to know about it. Some patients may also have very low educational level that they might be
concerned about their ability to perform well on cognitive testing and the embarrassment they
might experience especially with a computerized battery like the one in our study. We would
expect to see a higher incidence of POCD if such patients were involved in the study.
There was a higher representation of subjects with lower education level in the control
group than the patient group, though the difference between the two groups in education level
was not statistically significant. This difference could lead to different performance on cognitive
testing resulting in a difference in the magnitude of learning effects that occur in controls as
compared to patients, and consequently a potential bias in the incidence of POCD in the surgical
group.
Due to the small sample size, we had to combine anticholinergic and sedative-hypnotic
drugs in one category. We also were not able to tests the relationship between the total drug
burden taking into consideration the dose and regimen due to the small sample size.

IV. FUTURE DIRECTIONS
Future research should be directed towards conducting multicenter studies with larger
samples, more diverse population, and expanded types of major noncardiac surgery to increase
generalizability. Also, with appropriate funding and enough time, POCD should be assessed
several times over a longer period of time to capture the changes that occur to the cognitive
function of study subjects, and determine if POCD is a temporary or rather a permanent
condition. Also, it would be interesting to determine if there is an association between POCD
and AD since ApoE4 genotype has been associated with both conditions. The inflammatory
theory has a great potential to explain the etiology of POCD. However, we were not able to
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determine whether this is true in our study because we measured only one inflammatory
biomarker and only once before surgery without postoperative evaluation. We were testing the
hypothesis if patients with preoperative heightened inflammatory response may be at higher risk
for POCD three months after noncardiac surgery. However, it would be actually more promising
to test the hypothesis that patients who develop an inflammatory response during surgery may be
at higher risk for POCD by measuring the blood levels of more than one inflammatory
biomarkers that may play a role in the etiology of POCD (e.g., CRP, IL-1, IL-6, IL-8, TNFalpha) before and several times immediately after surgery at short intervals for at least 72 hours
especially that we do not know yet when each of these markers peaks in blood levels after being
released as an active response to inflammation during surgery. Our finding that using one or
more highly anticholinergic or sedative-hypnotic medications at home prior to surgery was
associated with POCD warrants future investigation of this relationship taking into consideration
the dose and duration of use of each of these medications. It might be also interesting to
investigate if discontinuing these drugs for a certain duration before surgery may decrease the
risk of POCD after surgery. Also, future research can investigate the possible protective effect of
certain anti-inflammatory drugs in decreasing the risk of POCD in patients undergoing different
types of surgery and anesthesia. Our finding that sevoflurane was associated with POCD
warrants further investigations by using randomized controlled trials comparing sevoflurane with
other general anesthetics to make a definitive conclusion whether sevoflurane causes POCD, and
if it does, whether it positions the patient at higher risk than other general anesthetics. It also
important to further investigate the mechanism by which sevoflurane might be causing cognitive
decline after surgery, and whether the tau phosphorylation theory is valid.
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V. CONCLUSION
POCD was present in about 16% of older adult patients three months after elective major
noncardiac surgery. Carrying the ApoE4 allele, using one or more highly anticholinergic or
sedative-hypnotic drugs prior to surgery, and receiving sevoflurane for anesthesia were risk
factors for long-term POCD. Suggestions for future research in this area include using larger
sample in a multicenter study, studying the association between the change in blood levels of
several potential inflammatory biomarkers before and after surgery and its association with
POCD, investigating the relationship between POCD and AD, studying the effect of dose and
duration of use of anticholinergic and sedative-hypnotic medications before surgery on the risk
of POCD, and investigating the protective effect of certain anti-inflammatory on decreasing the
risk of POCD in older adults after different types of surgery and anesthesia.
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APPENDIX A
Approved Consent form for Study Surgical Group

RESEARCH SUBJECT INFORMATION AND CONSENT FORM
TITLE: Risk Factors for the Development of Postoperative Cognitive Dysfunction in Older
Adults Undergoing Major Noncardiac Surgery
VCU IRB PROTOCOL NUMBER: HM13608
INVESTIGATORS:
Patricia W. Slattum, PharmD, PhD
Associate Professor and Director of Geriatric Pharmacotherapy Program
Department of Pharmacotherapy and Outcomes Science
VCU School of Pharmacy
Clarence J. Biddle, CRNA, PhD
Professor and Director of Research
Department of Nurse Anesthesia
VCU School of Allied Health Professions
Osama A. Shoair, BPharm
PhD Candidate, Geriatric Pharmacotherapy Program
Department of Pharmacotherapy and Outcomes Science
VCU School of Pharmacy
This consent form may contain words that you do not understand. Please ask the study staff to
explain any words or information that you do not clearly understand. You may take home an
unsigned copy of this consent form to think about or discuss with family or friends before
making your decision.
PURPOSE OF THE STUDY
The purpose of this study is to determine how often cognitive changes, such as changes in
memory, attention, information processing speed, reaction time, and mental flexibility, occur
after elective orthopedic surgery or neurosurgery in individuals 65 years or older and what the
risk factors are for increasing the likelihood of developing such cognitive changes after these
surgeries. Also, a secondary analysis will be done on the data collected to evaluate if there is a
relationship between older patients’ medications and diseases and their cognitive function.

94

DESCRIPTION OF THE STUDY
Before surgery, we will use computerized tests to evaluate your cognitive function, depression
status, and quality of sleep. After surgery, we will test you to see if you have delirium (an acute
condition that is characterized by feeling of confusion, difficulty in focusing, paying attention, or
organizing thoughts) that can possibly happen in some individuals 24 – 36 hours after surgery.
At discharge from the hospital, we will measure your cognitive function again using another set
of computerized tests. Finally, we will evaluate your cognitive function, depression status, and
sleep quality again 3 months after surgery and this will conclude the study.
In addition to computerized testing, you may opt to provide a 5-mL blood sample before surgery
for genetic testing that may help in the future to identify if there is a relationship between certain
genes and development of cognitive changes in individuals 65 years and older after elective
orthopedic surgery or neurosurgery.
You may also opt to provide a 5-mL blood sample before surgery for testing of an inflammatory
biomarker that may help in the future to identify if there is a relationship between preoperative
high level of this biomarker and development of cognitive changes in individuals 65 years and
older after elective orthopedic surgery or neurosurgery.
Information about you and your surgical procedure, including but not limited to, age, sex, race,
weight, height, educational level, alcohol intake, smoking status, previous surgeries, health
conditions, current medications, type and duration of anesthesia, duration of surgery, and other
surgical details will be collected from your medical records and evaluated in this study.
Your participation in this study will last for up to 3 months after your surgery. Approximately
150 subjects will participate in this study.
Significant new findings developed during the course of this research which may relate to your
willingness to continue participation will be provided to you.
PROCEDURES
If you decide to be in this research study, you will be asked to sign this consent form after you
have had all your questions answered.
During your visit to the preoperative assessment clinic, one of the study investigators will collect
the following information about you: demographics, age/date of birth, sex, race/ethnicity, weight,
height, educational level, computer familiarity, diagnosis on admission, previous/future
surgeries, current medications, health conditions, smoking status, and alcohol consumption. He
will also do a simple screening cognitive test to determine your eligibility for the study. This part
will take about 30 minutes to complete. If you are eligible to participate in the study, one of the
study investigators will evaluate your cognitive function, depression status, and sleep quality
using a computer test that will take about 30 minutes to complete.
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If you choose to provide a blood sample for testing of genetic and/or inflammatory biomarkers,
two 5-mL blood samples will be withdrawn from you on the day of the surgery just before the
induction of the anesthesia from the intravenous line that you will have by that time. Your
privacy will be protected by storing your blood samples labeled with a barcode that does not
contain your name or any personal information. Your personal information will be stored in a
secure computer database at VCU.
After your surgery and while you are still in the hospital, one test will be administered at 24 – 36
hours after surgery to evaluate if you have delirium (an acute condition that is characterized by
feeling of confusion, difficulty in focusing, paying attention, or organizing thoughts) after
surgery. This test should take from 5 – 15 minutes to complete. Also, another set of cognitive
tests will be administered at discharge from the hospital that should take about 30 minutes to
complete. Information about your surgical procedure, including but not limited to, type and
duration of anesthesia, duration of surgery, medications administered during surgery, and other
surgical details will be obtained from your surgical record.
Approximately 3 months after your surgery, another set of tests that measures your cognitive
function, depression status, and sleep quality will be administered and should take about 30
minutes. These measurements may take place at your doctor’s office during a regularly
scheduled visit or at your residence.
RISKS AND DISCOMFORTS
The computerized tests of cognitive function, depression status, and sleep quality that you will
take require only about 30 minutes per session to complete. The tests will be conducted in a
private quiet room at Virginia Commonwealth University Health System (VCUHS) where you
feel comfortable.
If you opt to provide a blood sample for genetic analysis, only 5-mL (one teaspoonful) of blood
will be withdrawn from you on the day of the surgery just before the induction of the anesthesia.
Risks of blood drawing (venipuncture) include bleeding, bruising, and fainting.
If you opt to provide a blood sample for biomarker analysis, only 5-mL (one teaspoonful) of
blood will be withdrawn from you on the day of the surgery just before the induction of the
anesthesia. Risks of blood drawing (venipuncture) include bleeding, bruising, and fainting.
The tests you will take at each session may show that you are having depression and/or poor
sleep quality. In either case, we will let you know immediately after the testing session and
encourage you to seek help from your primary care physician.
There is also a minimal risk of transmitting your personal identifying information to persons not
on the study team. However, we minimize this risk by immediately de-identifying this
information once we collect it from you and keeping it in a secure place that only study
personnel have access to.
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BENEFITS TO YOU AND OTHERS
There is no direct benefit to you for participating in this study, but what is learned from this
study may help other individuals undergoing elective orthopedic surgery or neurosurgery in the
future identify, minimize, or prevent their risk for developing cognitive decline after these types
of surgery and to understand the relationship between older patients’ medications and diseases
and their cognitive function.
If we find that your cognitive function appears to change during the study, you have experienced
depression, or if you are concerned about your cognitive function or depression test results, the
investigators will inform you and encourage you to see your primary care physician for further
evaluation.
COSTS
There are no charges at all for the study visits, or any cognitive, depression, or sleep quality tests.
There is also no cost at you to do blood genetic and/or biomarker testing if you opt to provide
blood samples for the purpose of conducting these tests.
PAYMENT FOR PARTICIPATION
You will receive a $25 VISA® gift card for completing the first set of cognitive function,
depression status, and sleep quality tests before your surgery. You will receive an additional $25
VISA® gift card for completing the confusion test 24 – 36 hours after surgery and the second set
of cognitive tests at discharge. You will receive a $50 VISA® gift card after the third set of
cognitive function, depression status, and sleep quality tests at 3 months after surgery for a total
of $100 in the form of VISA® gift cards if you completed all the study assessments. VISA® gift
cards can be used wherever VISA® debit cards are accepted. The cards cannot be reloaded or
used at ATM machines for cash withdrawals.
ALTERNATIVE
Your alternative is not to participate in this study.
CONFIDENTIALITY
Potentially identifiable information about you will consist of results from cognitive function,
depression status, sleep quality tests, and data abstracted from your medical record. This data is
being collected solely for research purposes. The data from cognitive function, depression status,
and sleep quality tests will be securely stored separately from medical records in a locked
research area and a secured computerized database at VCU.
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If you opt to provide blood samples for genetic and/or biomarker testing, they will be securely
stored at VCU School of Pharmacy. All personal identifying information will be kept in
password-protected files. Access to all data will be limited to study personnel who have
undergone special training on maintaining confidentiality of individuals participating in research.
You should know that research data or medical information about you may be reviewed or
copied by Virginia Commonwealth University. Although results of this research may be
presented at meetings or in publications, identifiable personal information pertaining to
participants will not be disclosed.
DATA FROM COGNITIVE FUNCTION, DEPRESSION STATUS AND SLEEP
QUALITY TESTING AND MEDICAL RECORD DATA
I give permission for my data from cognitive function, depression status and sleep quality
testing, and data from my medical record collected in this study to be stored and used for
research related to cognitive impairment in older adults, including but not limited to,
postoperative cognitive dysfunction and Alzheimer’s disease.
Yes
Yes, but I want to be contacted prior to any future use of my data for research
No
GENETIC TESTING
I opt to provide a 5-mL blood sample before surgery for genetic testing related to this research. I
understand that study investigators will not disclose individual test results to me or any other
third party.
Yes
No
I give permission for my genetic testing results to be stored and used for future research related
to cognitive impairment in older adults, including but not limited to, postoperative cognitive
dysfunction and Alzheimer’s disease.
Yes
Yes, but I want to be contacted prior to any future use of my data for research
No
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BIOMARKER TESTING
I opt to provide a 5-mL blood sample before surgery for testing of inflammatory biomarkers
related to this research. I understand that study investigators will not disclose individual test
results to me or any other third party.
Yes
No
I give permission for my biological markers testing results to be stored and used for future
research related to cognitive impairment in older adults, including but not limited to,
postoperative cognitive dysfunction and Alzheimer’s disease.
Yes
Yes, but I want to be contacted prior to any future use of my data for research
No
VOLUNTARY PARTICIPATION AND WITHDRAWAL
Your participation in this study is voluntary. You may decide not to participate in this study.
Your decision not to take part will involve no penalty or loss of benefits to which you are
otherwise entitled.
If you do participate, you may freely withdraw from the study at any time. Your decision to
withdraw will involve no penalty or loss of benefits to which you are otherwise entitled. You
may also choose to participate in the study but not provide blood samples for genetic and/or
biomarker testing. Your decision to participate in the study but not to provide blood samples will
involve no penalty or loss of benefits to which you are otherwise entitled.
Your participation in this study may be stopped at any time without your consent. The reasons
might include, but not limited to, that you have not followed study instructions, there are
administrative reasons that require your withdrawal, or that we have stopped the study.
QUESTIONS
In the future, you may have questions about your study participation. If you have any questions,
complaints, or concerns about the research, contact:
Patricia W. Slattum, PharmD, PhD
Director, Geriatric Pharmacotherapy Program
Virginia Commonwealth University
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410 N 12th Street, Smith Building, Room 656A
Richmond, VA 23298-0533
PO Box 980533
(804) 828-6355
If you have questions about your rights as a research subject, you may contact:
Office of Research
Virginia Commonwealth University
800 East Leigh Street, Suite 113
PO Box 980568
Richmond, VA 23298
(804) 827-2157
You may also contact this number for general questions, concerns or complaints about the
research. Please, call this number if you cannot reach the research team or wish to talk to
someone else.
Do not sign this consent form unless you have had a chance to ask questions and have received
satisfactory answers to all of your questions. Additional information about participation in
research studies can be found at http://www.research.vcu.edu/irb/volunteers.htm.
CONSENT
I have been provided with an opportunity to read this consent form carefully. All of the questions
that I wish to raise concerning this study have been answered. By signing this consent form, I
have not waived any of the legal rights or benefits, to which I otherwise would be entitled. My
signature indicates that I freely consent to participate in this research study. I will receive a copy
of the consent form once I have agreed to participate.
_______________________________________________________________________
Subject Name, printed
Subject Signature
Date
________________________________________________
Name of Person Conducting Informed Consent
Discussion / Witness
(Printed)
________________________________________________ ________________
Signature of Person Conducting Informed Consent
Date
Discussion / Witness
________________________________________________ ________________
Principal Investigator Signature (if different from above)
Date
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APPENDIX B
Approved Consent form for Study Nonsurgical Group
RESEARCH SUBJECT INFORMATION AND CONSENT FORM
TITLE: Risk Factors for the Development of Postoperative Cognitive Dysfunction in Older
Adults Undergoing Major Noncardiac Surgery
VCU IRB PROTOCOL NUMBER: HM13608
INVESTIGATORS:
Patricia W. Slattum, PharmD, PhD
Associate Professor and Director of Geriatric Pharmacotherapy Program
Department of Pharmacotherapy and Outcomes Science
VCU School of Pharmacy
Clarence J. Biddle, CRNA, PhD
Professor and Director of Research
Department of Nurse Anesthesia
VCU School of Allied Health Professions
Osama A. Shoair, BPharm
PhD Candidate, Geriatric Pharmacotherapy Program
Department of Pharmacotherapy and Outcomes Science
VCU School of Pharmacy
This consent form may contain words that you do not understand. Please ask the study staff to
explain any words or information that you do not clearly understand. You may take home an
unsigned copy of this consent form to think about or discuss with family or friends before
making your decision.
PURPOSE OF THE STUDY
The purpose of this study is to determine how often cognitive changes, such as changes in
memory, attention, information processing speed, reaction time, and mental flexibility, occur
after elective orthopedic surgery or neurosurgery in patients 65 years and older and to identify
the risk factors for increasing the likelihood of such cognitive changes after these surgeries. Also,
a secondary analysis will be done on the data collected to evaluate if there is a relationship
between older patients’ medications and diseases and their cognitive function.
In order to accurately measure changes in cognitive function in older patients undergoing surgery
in our study, we need to recruit a control group of older adults who are not undergoing surgery
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within 3 months and measure their cognitive function at the same time interval as the patients in
our study (baseline and 3 months later) to compare the change in cognitive function between the
patient and control groups.
DESCRIPTION OF THE STUDY
We will use a computer program called CNS Vital Signs™ to assess your cognitive function,
depression status, and sleep quality at your first meeting with us and again 3 months later to see
if there is any significant change in your cognitive function. It will take about 30 minutes to
complete all the tests at each of the two sessions. These tests may take place at your residence or
at a private quiet room at VCU Health System.
Your participation in this study will last for about 3 months after your first interview with the
study team. Approximately 100 subjects will participate in this study as controls. Significant new
findings developed during the course of this research which may relate to your willingness to
continue participation will be provided to you.
PROCEDURES
If you decide to be in this research study as a control, you will be asked to sign this consent form
after you have had all your questions answered.
If you decide to be part of the study, the research team will conduct their first interview with you
either at VCU Health System or at your residence. During this first interview, the study
investigators will collect information about your age, gender, race, education level, computer
familiarity, smoking status, alcohol consumption, health conditions, future surgeries, and current
medications.
We will also do a simple screening cognitive test to determine your eligibility for the study. If
you are eligible to participate in the study, one of the study investigators will evaluate your
cognitive function, depression status, and sleep quality using a computer test that will take about
30 minutes to complete.
Approximately 3 months after your first interview, we will arrange another meeting with you at
VCU Health System or at your residence to evaluate your cognitive function, depression status,
and sleep quality again using the same tests from the first interview which will take about 30
minutes to complete. We will also check if there has been any change to your current
medications.
RISKS AND DISCOMFORTS
The computerized tests of cognitive function, depression status, and sleep quality that you will
take require only about 30 minutes per session to complete. The tests will be conducted in a
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private quiet room at VCU Health System or your residence where you feel comfortable. There
are times in between different tests when you can take a break if you want to. If you feel
exhausted at any time, you can stop the testing session.
The tests you will take at each session may show that you are having depression and/or poor
sleep quality. In either case, we will let you know immediately after the testing session and
encourage you to seek help from your primary care physician.
There is also a minimal risk of transmitting your personal identifying information to persons not
on the study team. However, we minimize this risk by immediately de-identifying this
information once we collect it from you and keeping it in a secure place that only study
personnel have access to.
BENEFITS TO YOU AND OTHERS
There is no direct benefit to you for participating in this study, but what is learned from this
study by comparing the change in cognitive function between study patients and controls from
baseline to the 3-month follow-up may help in the future to minimize or prevent the risk for
developing cognitive decline after elective orthopedic surgery or neurosurgery in older adults
and to understand the relationship between older patients’ medications and diseases and their
cognitive function.
If the cognitive screening test shows that you have a cognitive problem or if we find that you
may have depression or poor sleep quality, the study investigators will inform you and encourage
you to talk to your primary care physician for further evaluation.
COSTS
There are no charges at all for the study visits, or any cognitive, depression, or sleep quality tests.
PAYMENT FOR PARTICIPATION
You will receive a $25 VISA® gift card for completing the cognitive function, depression status,
and sleep quality tests at your first interview. You will receive an additional $50 VISA® gift
cards for completing the cognitive function, depression status, and sleep quality tests at your
second interview for a total of $75 in the form of VISA® gift cards if you complete both study
assessments. VISA® gift cards can be used wherever VISA® debit cards are accepted. The cards
cannot be reloaded or used at ATM machines for cash withdrawals.
ALTERNATIVE
Your alternative is not to participate in this study.

103

CONFIDENTIALITY
Information about your age, gender, race, education level, computer familiarity, smoking status,
alcohol consumption, health conditions, future surgeries, and current medications in addition to
your results of cognitive function, depression status, and sleep quality tests is being collected
solely for research purposes. This data will be securely stored in a locked research area and a
secured computerized database at VCU. Access to all data will be limited to study personnel who
have undergone special training on maintaining confidentiality of individuals participating in
research.
You should know that research data or medical information about you may be reviewed or
copied by Virginia Commonwealth University. Although results of this research may be
presented at meetings or in publications, identifiable personal information pertaining to
participants will not be disclosed.
FUTURE USE OF DATA
I give permission for my data collected in this study to be stored and used for research related to
cognitive impairment in older adults. (Please, check and initial your choice)
Yes ______
Yes, but I want to be contacted prior to any future use of my data for research ______
No ______
VOLUNTARY PARTICIPATION AND WITHDRAWAL
Your participation in this study is voluntary. You may decide not to participate in this study.
Your decision not to take part will involve no penalty or loss of benefits to which you are
otherwise entitled. If you participate, you may freely withdraw from the study at any time. Your
decision to withdraw will involve no penalty or loss of benefits you are otherwise entitled to.
Your participation in this study may be stopped at any time without your consent. The reasons
might include, limited to, that you have not followed study instructions, there are administrative
reasons that require your withdrawal, or that we have stopped the study.
QUESTIONS
In the future, you may have questions about your study participation. If you have any questions,
complaints, or concerns about the research, contact the study principal investigator:
Patricia W. Slattum, PharmD, PhD
Director, Geriatric Pharmacotherapy Program
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Virginia Commonwealth University
410 N. 12th Street, Smith Building, Room 656A, P.O. Box 980533
Richmond, VA 23298-0533
(804) 828-6355
If you have questions about your rights as a research subject, you may contact:
Office of Research
Virginia Commonwealth University
800 East Leigh Street, Suite 113
PO Box 980568
Richmond, VA 23298
(804) 827-2157
You may also contact this number for general questions, concerns or complaints about the
research. Please, call this number if you cannot reach the research team or wish to talk to
someone else.
Do not sign this consent form unless you have had a chance to ask questions and have received
satisfactory answers to all of your questions. Additional information about participation in
research studies can be found at http://www.research.vcu.edu/irb/volunteers.htm
CONSENT
I have been provided with an opportunity to read this consent form carefully. All of the questions
that I wish to raise concerning this study have been answered. By signing this consent form, I
have not waived any of the legal rights or benefits, to which I otherwise would be entitled. My
signature indicates that I freely consent to participate in this research study. I can request a copy
of the signed consent form once I have agreed to participate.
_______________________________________________________________________
Subject Name, printed
Subject Signature
Date
________________________________________________
Name of Person Conducting Informed Consent
Discussion / Witness
(Printed)
________________________________________________ ________________
Signature of Person Conducting Informed Consent
Date
Discussion / Witness
______________________________________________
Principal Investigator Signature (if different from above)
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________________
Date
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